US20240043479A1 - Malassezia factor with antibiotic activity - Google Patents
Malassezia factor with antibiotic activity Download PDFInfo
- Publication number
- US20240043479A1 US20240043479A1 US18/381,047 US202318381047A US2024043479A1 US 20240043479 A1 US20240043479 A1 US 20240043479A1 US 202318381047 A US202318381047 A US 202318381047A US 2024043479 A1 US2024043479 A1 US 2024043479A1
- Authority
- US
- United States
- Prior art keywords
- composition
- malassezia
- aureus
- cfs
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000555676 Malassezia Species 0.000 title claims abstract description 67
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 118
- 239000006228 supernatant Substances 0.000 claims abstract description 19
- 241000191940 Staphylococcus Species 0.000 claims abstract description 16
- 239000003937 drug carrier Substances 0.000 claims abstract description 14
- 241001291478 Malassezia sympodialis Species 0.000 claims description 57
- 230000012010 growth Effects 0.000 claims description 33
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 239000006071 cream Substances 0.000 claims description 17
- 230000000845 anti-microbial effect Effects 0.000 claims description 15
- 241001291474 Malassezia globosa Species 0.000 claims description 13
- 241001291477 Malassezia restricta Species 0.000 claims description 12
- 241001147695 Staphylococcus caprae Species 0.000 claims description 12
- 241000192086 Staphylococcus warneri Species 0.000 claims description 12
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 10
- 229960003085 meticillin Drugs 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 239000005414 inactive ingredient Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 241000555688 Malassezia furfur Species 0.000 claims description 8
- 241001299738 Malassezia pachydermatis Species 0.000 claims description 8
- 108010059993 Vancomycin Proteins 0.000 claims description 7
- 229960003165 vancomycin Drugs 0.000 claims description 7
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 7
- 239000003205 fragrance Substances 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 5
- 241000428512 Malassezia dermatis Species 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 20
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 36
- 238000009472 formulation Methods 0.000 description 24
- 239000001974 tryptic soy broth Substances 0.000 description 21
- 108010050327 trypticase-soy broth Proteins 0.000 description 21
- 230000000699 topical effect Effects 0.000 description 18
- 239000004599 antimicrobial Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000003995 emulsifying agent Substances 0.000 description 12
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 12
- 229960001019 oxacillin Drugs 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- -1 fatty acid salts Chemical class 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 206010040872 skin infection Diseases 0.000 description 9
- 241000295644 Staphylococcaceae Species 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003974 emollient agent Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000006585 stringent response Effects 0.000 description 6
- 239000002132 β-lactam antibiotic Substances 0.000 description 6
- 229940124586 β-lactam antibiotics Drugs 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000012268 genome sequencing Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 3
- 229960001082 trimethoprim Drugs 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004184 Avoparcin Substances 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241001147736 Staphylococcus capitis Species 0.000 description 2
- 241000192087 Staphylococcus hominis Species 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108010080702 Virginiamycin Proteins 0.000 description 2
- 239000004188 Virginiamycin Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 229950001335 avoparcin Drugs 0.000 description 2
- JWFVWARSGMYXRN-HTQQBIQNSA-N avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 description 2
- 235000019377 avoparcin Nutrition 0.000 description 2
- 108010053278 avoparcin Proteins 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- 229940095077 behentrimonium methosulfate Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 229960002100 cefepime Drugs 0.000 description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2
- 229960000466 cefpirome Drugs 0.000 description 2
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- QIVLQXGSQSFTIF-UHFFFAOYSA-M docosyl(trimethyl)azanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C QIVLQXGSQSFTIF-UHFFFAOYSA-M 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960000740 enrofloxacin Drugs 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 2
- 229960004675 fusidic acid Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 229940020707 synercid Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2
- 229960004659 ticarcillin Drugs 0.000 description 2
- 229940100611 topical cream Drugs 0.000 description 2
- 229940042129 topical gel Drugs 0.000 description 2
- 229960003842 virginiamycin Drugs 0.000 description 2
- 235000019373 virginiamycin Nutrition 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010055400 Aspartate kinase Proteins 0.000 description 1
- 101001022844 Bacillus subtilis ATP-dependent proline adenylase Proteins 0.000 description 1
- 101000644385 Brevibacillus parabrevis ATP-dependent leucine adenylase Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 241000074453 Cainiella borealis Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 108010000898 Chorismate mutase Proteins 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108010021555 GTP Pyrophosphokinase Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 108010064711 Homoserine dehydrogenase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 241000368104 Malassezia sympodialis ATCC 42132 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000036848 Porzana carolina Species 0.000 description 1
- 102000010975 RNA recognition motif domains Human genes 0.000 description 1
- 108050001169 RNA recognition motif domains Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000750300 Staphylococcus aureus MW2 Species 0.000 description 1
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 1
- 241001147687 Staphylococcus auricularis Species 0.000 description 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000010899 TGS Human genes 0.000 description 1
- 108010029287 Threonine-tRNA ligase Proteins 0.000 description 1
- 102100034997 Threonine-tRNA ligase, mitochondrial Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000009166 cellular response to nutrient Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940073642 ceteareth-30 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229940049292 n-(3-(dimethylamino)propyl)octadecanamide Drugs 0.000 description 1
- WWVIUVHFPSALDO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C WWVIUVHFPSALDO-UHFFFAOYSA-N 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940119519 peg-32 stearate Drugs 0.000 description 1
- 229940119517 peg-6 stearate Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000027086 plasmid maintenance Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000037948 vancomycin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- compositions with antibiotic activity relate to compositions with antibiotic activity and methods of their use, particularly for inhibiting Staphylococcus aureus.
- pathogens As pathogens encounter new host environments, abiotic factors such as temperature, pH, and nutrient supply influence pathogen survival and disease outcomes. Equally important are the biotic factors encountered by invading pathogens including host cellular and humoral defenses as well as host-associated microbes. As a result, these resident microbes exert strong selective pressures driving pathogen evolution. Currently, examples of these influential microbial interactions are largely limited to those between bacteria, and it remains unclear how interactions with resident fungi influence pathogen evolution and disease outcomes
- fungi are able to modulate bacterial growth, virulence, and antibiotic sensitivity.
- the human skin is a major barrier to infection and is colonized by an estimated 10 6 to 10 9 microorganisms per cm 2 , of which the relative abundance of fungi is estimated to be 10 times greater in some regions than observed within the gut microbiome.
- Staphylococcus aureus is a chronic asymptomatic colonizer of the nose in humans, but only transiently colonizes the skin.
- S. aureus skin colonization is a major risk factor for skin and soft tissue infections that amount to approximately a half of a million annual hospitalization in the United States. Additionally, S. aureus skin colonization and toxin production have been associated with multiple cancers. Thus, understanding obstacles to S. aureus skin colonization is a point of great interest in promoting human health.
- antimicrobial compositions derived from the fungus Malassezia .
- Such compositions are useful for treating or inhibiting bacterial growth or infection, particularly growth of, or infection with Staphylococcus aureus .
- the disclosed compositions include a Malassezia exoproduct, a Malassezia cell free supernatant (CFS), or a Malassezia cell; and a pharmaceutically acceptable carrier.
- the Malassezia is Malassezia sympodialis, Malassezia restricta , or Malassezia globosa .
- the Malassezia exoproduct has one or more characteristics of heat resistance, binding to non-polar molecules, and pH sensitivity (for example, antimicrobial activity at pH of about 6 or less).
- the composition inhibits growth and/or infection with a Staphylococcus species, for example, S. aureus , methicillin-resistant S. aureus , vancomycin-resistant S. aureus, S. caprae, S. epidermidis, S. haemolyticus , or S. warneri .
- a Staphylococcus species for example, S. aureus , methicillin-resistant S. aureus , vancomycin-resistant S. aureus, S. caprae, S. epidermidis, S. haemolyticus , or S. warneri .
- the composition inhibits growth of a Staphylococcus species by at least 10-fold compared to a control.
- the composition includes about 0.01%-10% w/w, 0.01-10% v/v, or 0.01-10% w/v of the Malassezia exoproduct, cell free supernatant, or cells.
- the composition further includes one or more additional antibiotic compounds.
- the composition is formulated for topical administration, such as a solution, gel, ointment, cream, or suspension.
- the pharmaceutically acceptable carrier is a base including a plurality of inactive ingredients.
- kits for treating or inhibiting bacterial growth, infection, and/or skin colonization in a subject include administering a disclosed composition to the subject.
- the bacteria is a Staphylococcus species (for example, S. aureus , methicillin-resistant S. aureus , vancomycin-resistant S. aureus, S. caprae, S. epidermidis, S. haemolyticus , or S. warneri ).
- the subject has a bacterial skin infection, such as a skin infection with S. aureus , methicillin-resistant S. aureus , or vancomycin-resistant S. aureus.
- the composition is administered orally or intravenously. In other embodiments, the composition is administered topically, for example to the skin, such as at the site of a skin infection. In some examples, the methods include administering an additional antibiotic therapy to the subject, for example, prior to, concurrently with, or following treatment with the composition.
- FIGS. 1 A- 1 C show that Malassezia exoproducts inhibit S. aureus .
- FIG. 1 A is an image showing S. aureus spotted on agar plates adjacent to 72 hour Malassezia colonies and grown for 24 hours. S. aureus cannot grow up to the colony.
- FIG. 1 B is a graph showing that S. aureus colony forming units (CFUs) per mL were not significantly reduced after 2 hour treatment with cell-free supernatant (CFS) collected from M. furfur and mixed 1:1 with fresh media (50% CFS).
- CFS from M. pachydermatis resulted in a small but significant reduction in S. aureus CFUs/mL and CFS from M.
- FIG. 1 C is a graph showing that S. aureus colony forming units (CFUs) per mL were reduced after 2 hour treatment with cell-free supernatant (CFS) collected from M. sympodialis (Ms), M. restricta (Mr), or M. globosa (Mg).
- CFS cell-free supernatant
- FIGS. 2 A and 2 B show antimicrobial activity of M. sympodialis targets particular staphylococci.
- FIG. 2 A is a heat-map showing forming units enumerated to calculate the proportion of bacteria surviving the indicated CFS treatment relative to the media control.
- Se S. epidermidis ; Sc: S. caprae ; Sho: S. hominis ; Sl: S. lugdunensis ; Sw: S. warneri ; Sca: S. capitis ; Sa: S. aureus ; Sha: S haemolyticus .
- FIG. 2 B is a graph showing CFU/ml of S. aureus (strain HFH) and six S. epidermidis strains treated with 50% CFS from M. sympodialis (strain KS269) or pH-matched media control (mDixon) for 6 hours.
- FIGS. 3 A and 3 B show characterization of antimicrobial activity produced by M. sympodialis .
- FIG. 3 A is a graph showing that toxicity of CFS collected from M. sympodialis KS269 was not abolished after boiling (30 min., 98° C.). Adjustment of the CFS pH from pH 5.4-5.6 to pH 6 with NaOH reduced CFS toxicity to S. aureus . The toxic effector was removed from the CFS following exposure to a non-polar resin.
- FIG. 3 B is a graph showing treatment of S. aureus with CFS was bactericidal after 3 hours, resulting in >10,000-fold reduction in S. aureus CFUs. In contrast to wild-type (WT) S. aureus , a clean deletion mutant lacking fatty acid kinase ( ⁇ fakA) was only slightly sensitive to treatment with M. sympodialis CFS.
- WT wild-type
- ⁇ fakA a clean deletion mutant
- FIGS. 4 A- 4 E show S. aureus adapts to serially exposure to CFS through mutation in the stringent response regulator Sa-Rel.
- FIG. 4 A is a schematic diagram of protocol for experimental evolution of S. aureus exposed to 50% CFS from M. sympodialis .
- FIG. 4 A is a schematic diagram of protocol for experimental evolution of S. aureus exposed to 50% CFS from M. sympodialis .
- FIG. 4 C is an image of Ancestral, WT-like white isolates (left) and the evolved, CFS-resistant hyperpigmented yellow isolates (right).
- FIG. 4 D is a graph of recovered CFU/mL of pH-matched media treated (mDixon) or +50% CFS treated white and yellow colonies from EVOL-P1 replicate from passage 12 .
- FIG. 4 E is a schematic diagram of Sa-Rel protein with mutations identified in the C199 strain from the experimental evolution (EVOL-P1, -P2, P3) and the mixed-biofilm experiment (IsoA) and from the additional HFH strain used in experimental evolution (HFH EVOL-P3).
- HD hydrolase domain
- SYNTH synthetase domain
- TGS ThrRS, GTPase, and SpoT domain
- ACT/RRM Aspartokinase, Chorismate mutase and TyrA/RNA Recognition Motif domain.
- FIGS. 5 A- 5 C show S. aureus growth in the presence of the ⁇ -lactam oxacillin. Growth in TSB with 0 ⁇ g/mL oxacillin ( FIG. 5 A ), growth in TSB with 4 ⁇ g/mL oxacillin ( FIG. 5 B ), and growth in TSB with 16 ⁇ g/mL oxacillin ( FIG. 5 C ).
- FIGS. 6 A- 6 C show that M. sympodialis CFS reduces S. aureus survival on human skin explants.
- FIG. 6 A is an image of an 11 mm NativeSkin® explant biopsy.
- FIG. 6 B shows detection of red fluorescent protein (RFP)-expressing S. aureus after 24 hours on human skin biopsy at 24 hours.
- FIG. 6 C is a graph showing S. aureus recoverable CFU on skin explants after 24 hours of S. aureus colonization followed by treatment with pH control or CFS mixed 1:1 with PBS across three independent donors.
- RFP red fluorescent protein
- an isolated biological component is one in which the biological component is more enriched than the biological component is in its standard environment or a production vessel.
- a preparation is purified such that the biological component represents at least 50%, such as at least 70%, at least 90%, at least 95%, or greater, of the total biological component content of the preparation.
- Malassezia A genus of fungi found on the skin of humans and other animals. It is typically commensal, but can cause opportunistic infections, such as seborrheic dermatitis or atopic dermatitis.
- Exemplary Malassezia species include M. dermatis, M. furfur, M. globosa, M. pachydermatis, M. restricta , and M. sympodialis .
- the Malassezia species is Malassezia sympodialis. M.
- sympodialis is a common commensal of normal human skin microbiota; however, it can cause skin disorders such as pityriasis versicolor, seborrheic dermatitis, and atopic dermatitis in some situations.
- Exemplary reference Malassezia genomes and strains are known and are publicly available.
- Exemplary strains include M. sympodialis KS269, M. sympodialis ATCC 96803, M. sympodialis ATCC 42132, M. globosa ATCC MYA-4612D-5, M. globosa ATCC MYA-4612, and M. restricta ATCC MYA-4611.
- S. aureus forms a fairly large yellow colony on rich medium. By comparison, S. epidermidis forms a relatively small white colony. S. aureus is often hemolytic on blood agar while S. epidermidis is non-hemolytic. Staphylococci are facultative anaerobes that grow by aerobic respiration or by fermentation that yields principally lactic acid. The bacteria are catalase-positive and oxidase-negative. S. aureus can grow at a temperature range of 15° C. to 45° C. and at NaCl concentrations as high as 15 percent. Nearly all strains of S. aureus produce the enzyme coagulase. In contrast, nearly all strains of S. epidermidis lack this enzyme. Thus, strains of S. epidermidis are often referred to as coagulase-negative staphylococci.
- Staphylococcus is S. aureus , which is usually a commensal of the human microbiota, but is also an opportunistic pathogen that can cause skin infections (including abscesses), respiratory infections, meningitis, toxic shock syndrome, and sepsis.
- S. aureus has become resistant to many antibiotics.
- S. aureus also includes antibiotic-resistant S. aureus , such as methicillin-resistant S. aureus (MRSA) and/or vancomycin-resistant S. aureus (VRSA).
- Malassezia is the dominant fungal genus on human skin. Interactions between Malassezia and bacteria are described herein, including identification of one or more compounds secreted by Malassezia that exhibit antibiotic effects.
- the one or more compounds inhibit growth of S. aureus (including MRSA), S. caprae, S. epidermidis, S. haemolyticus , and/or S. warneri .
- the one or more compounds exhibit a bactericidal activity.
- exoproducts produced by Malassezia species such as M. sympodialis, M. restricta , or M. globosa ) capable of inhibiting growth of Staphylococcus (including S. aureus ), e.g., exhibiting antimicrobial activity.
- the antimicrobial factor is a compound produced by and/or secreted by Malassezia .
- the Malassezia is M. sympodialis, M. restricta , or M. globosa .
- the antimicrobial factor exhibits one or more properties including heat resistance (for example, retention of antimicrobial 98° C.
- the antimicrobial factor has a molecular weight of about 2000 Da or less (e.g., based on binding to non-polar resin as described in Example 3). In other examples, the antimicrobial factor may form aggregates of about 30 kDa or more (e.g., as described in Example 3). In some embodiments, the antimicrobial factor (such as the Malassezia exoproduct) may be a lipid or other non-polar molecule. In other embodiments, the antimicrobial factor (such as the Malassezia exoproduct) is not a protein. In additional embodiments, a fatty acid kinase (fakA) mutant of S. aureus is resistant to the antimicrobial factor.
- fakA fatty acid kinase
- the antimicrobial factor inhibits growth of one or more Staphylococcus species, such as inhibits growth of one or more of S. aureus, S. caprae, S. epidermidis, S. haemolyticus , and S. warneri compared to a control.
- a disclosed antimicrobial factor inhibits growth of one or more of S. aureus, S. caprae, S. epidermidis, S. haemolyticus , and S.
- warneri by at least about 10-fold (such as at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or more) compared to a control, such as untreated S. aureus, S. caprae, S. epidermidis, S. haemolyticus , or S. warneri .
- a disclosed antimicrobial factor specifically inhibits growth of one or more of S. aureus, S. caprae, S. epidermidis, S. haemolyticus , and S. warneri , for example, inhibits growth of one or more of S. aureus, S.
- S. epidermidis caprae, S. epidermidis, S. haemolyticus , and S. warneri by at least about 10-fold (such as at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or more), but inhibits growth of other Staphylococcus species by less than about 10-fold (such as less than about 5-fold, less than about 2-fold, or less than 50%) compared to a control (such as the untreated Staphylococcus species).
- a control such as the untreated Staphylococcus species.
- compositions including a Malassezia exoproduct (such as a M. sympodialis exoproduct, a M. restricta exoproduct, or a M. globosa exoproduct) capable of inhibiting growth of Staphylococcus (for example, one or more of S. aureus , MRSA, VRSA, S. caprae, S. epidermidis, S. haemolyticus , and S. warneri ) and a pharmaceutically acceptable carrier.
- a Malassezia exoproduct such as a M. sympodialis exoproduct, a M. restricta exoproduct, or a M. globosa exoproduct
- Staphylococcus for example, one or more of S. aureus , MRSA, VRSA, S. caprae, S. epidermidis, S. haemolyticus , and S. warneri
- a cell-free supernatant from a Malassezia species such
- compositions including Malassezia (such as M. sympodialis ) cells and a pharmaceutically acceptable carrier.
- Malassezia such as M. sympodialis
- the composition includes live Malassezia cells (such as active or dormant M. sympodialis, M. restricta , or M. globosa cells).
- compositions comprising the antimicrobial (e.g., antibiotic) compounds disclosed herein may be formulated in a variety of ways depending, for example, on the mode of administration and/or on the location and type of infection to be treated.
- such pharmaceutical compositions may be formulated as pharmaceutically acceptable salts.
- parenteral formulations may comprise injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like.
- Excipients may include, for example, nonionic solubilizers, such as cremophor, or proteins, such as human serum albumin or plasma preparations.
- the pharmaceutical composition to be administered may also contain non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example, sodium acetate or sorbitan monolaurate.
- compositions comprising antibiotic compounds as described herein may be formulated in unit dosage form suitable for individual administration of precise dosages.
- the amount and route of administration of a therapeutic compound administered will depend on the subject being treated, the type and severity of the infection, and the manner of administration, and is known to those skilled in the art.
- the formulation to be administered will contain a quantity of the antibiotic compounds disclosed herein in an amount effective to achieve the desired effect in the subject being treated (e.g., reducing or eliminating Staphylococcus pathogens).
- the composition includes about 0.01-10% (w/v or v/v) of the active composition (exoproduct, cell-free supernatant, or cells), for example, about 0.01-0.1%, about 0.05%-0.5%, about 0.25%-1%, about 0.75%-1.5%, about 1-2.5%, about 2-5%, about 3-6%, about 4-8%, about 5-7.5%, or about 6-10%.
- the composition includes about 10 2 -10 9 Malassezia cells (such as M. sympodialis, M. restricta , or M. globosa cells), for example, about 10 2 -10 4 cells, about 10 3 -10 5 cells, about 10 4 -10 6 cells, about 10 5 -10 7 cells, about 10 6 -10 8 cells, or about 10 7 -10 9 cells.
- the composition includes one or more additional antibiotic compounds, for example, one or more of clindamycin, erythromycin, tetracycline, minocycline, doxycycline, penicillin, ampicillin, carbenicillin, methicillin, cephalosporins, vancomycin, bacitracin, streptomycin, gentamycin, chloramphenicol, fusidic acid, ciprofloxin and other quinolones, sulfonamides, trimethoprim, dapsone, isoniazid, teicoplanin, avoparcin, synercid, virginiamycin, cefotaxime, ceftriaxone, piperacillin, ticarcillin, cefepime, cefpirome, rifampicin, pyrazinamide, ciprofloxacin, levofloxacin, enrofloxacin, amikacin, netilmycin, imipenem, meropenem,
- compositions may include carriers such as solid carriers (e.g., finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like), liquid carriers (e.g., water, dimethyl sulfoxide (DMSO), alcohols, glycols, or water-alcohol/glycol blends, optionally with the aid of non-toxic surfactants), and/or thickeners (e.g., synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses, or modified mineral materials).
- solid carriers e.g., finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like
- liquid carriers e.g., water, dimethyl sulfoxide (DMSO), alcohols, glycols, or water-alcohol/glycol blends, optionally with the aid of non-toxic surfactants
- thickeners e.g., synthetic polymers, fatty
- compositions e.g., Malassezia exoproduct(s), CFS, or cells
- compositions may be formulated as solutions, gels, ointments, creams, suspensions, etc.
- Particular embodiments of formulations for use in the methods described herein include a therapeutically effective amount of the compound, a topical base, an antioxidant, an emollient, and an emulsifier.
- a therapeutically effective amount of the compound may vary, but typically the therapeutically effective amount is from 0.01% to 10% (w/w).
- Embodiments of a topical compositions include a base including a plurality of inactive ingredients.
- the base is a topical cream or topical gel base.
- the inactive ingredients may include, but are not limited to, acrylates/C10-30 alkyl acrylate crosslinked polymer (e.g., Carbopol® Ultrez 21 polymer, Lubrizol Advanced Materials, Cleveland, OH), colloidal silver (e.g., Bio-Active Silver HydrosolTM, Natural Immunogenics, Inc., Pompano Beach, FL), fulvic liquid minerals, potassium sorbate, vegetable glycerin (USP grade), citric acid, water, sodium hydroxide, crosslinked poly(acrylic acid) (e.g., Carbopol® Ultrez 30 polymer), caprylyl glycol, ethylhexylglycerin, or any combination thereof.
- acrylates/C10-30 alkyl acrylate crosslinked polymer e.g., Carbopol® Ultrez
- sodium hydroxide functions as an emulsifier and buffer, and may thicken a polymer gel base.
- Colloidal silver may be utilized as an antimicrobial agent.
- the water is purified water or positively charged acidic water.
- the fulvic minerals may be any of various compositions extracted from fulvic mineral bases.
- the topical base may include polyethylene glycol having a selected molecular weight. Particular embodiments comprise a polyethylene glycol having a molecular weight of from 3000 to 8000 daltons as a topical base.
- the formulation is an ointment, and may further include a water-miscible solvent, such as a polyalkylene glycol having an average molecular weight of from 200 daltons to 600 daltons.
- a water-miscible solvent such as a polyalkylene glycol having an average molecular weight of from 200 daltons to 600 daltons.
- the water-miscible solvent comprises PEG-400, and even more particularly PEG-400 substantially free of impurities.
- the base may include one, all, or any of the above-listed inactive ingredients, or other inactive ingredients, in any desired ratio to produce a desired viscosity, a desired dry time on the skin, a desired scent, a desired shelf life, a desired biological activity, or any other desired characteristic of property of a topical gel or cream composition.
- the base may further comprise 0.1-5 wt % ethanol to facilitate drying of the gel of cream on a subject's skin and/or to achieve a desired viscosity.
- the disclosed topical compositions may be packaged in any suitable manner.
- the topical composition may be packaged into a pump bottle (e.g., an airless pump bottle), a squeeze bottle, a plastic tube, a metallic tube, an automatic dispensing tube, an ampoule, a jar, a tin, or any other packaging material capable of containing and, optionally, preserving potency and/or efficacy of the active agents of the topical composition.
- a pump bottle e.g., an airless pump bottle
- a squeeze bottle e.g., a squeeze bottle
- plastic tube e.g., a plastic tube
- a metallic tube e.g., a metallic tube
- an automatic dispensing tube e.g., an ampoule, a jar, a tin, or any other packaging material capable of containing and, optionally, preserving potency and/or efficacy of the active agents of the topical composition.
- Topical formulations for use as described herein also can include a penetration enhancer, such as dimethyl isosorbide, propylene glycol, or combinations thereof; an emollient, such as water; a surfactant, such as sorbitan monostearate, a polyethylene glycol monostearate, D- ⁇ -tocopheryl polyethylene glycol 1000 succinate, a composition comprising glycol stearate/PEG32 stearate/PEG6 stearate, and combinations of surfactants; an antioxidant, such as butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, a tocopherol, and combinations thereof, with particular embodiments comprising butylated hydroxytoluene as an antioxidant; and an optional colorant.
- a penetration enhancer such as dimethyl isosorbide, propylene glycol, or combinations thereof
- an emollient such as water
- a surfactant such as sorbitan monostearate, a poly
- the formulation is a solution. In another embodiment, the formulation is a gel. In another embodiment, the formulation is a suspension. In yet another embodiment, the formulation is a cream or ointment.
- the formulation is a liquid, for example a homogeneous liquid or a suspension, sold in a bottle which dispenses the formulation as drops or a liquid film (for example from an applicator tip that contacts a target area of the skin to dispense the liquid substantially only on a target area of the skin to be treated).
- the formulation is a cream or ointment, sold in a tube which dispenses the formulation to a target area of the skin.
- the compound is provided in a viscous liquid (such as carboxylmethylcellulose, hydroxypropylmethycellulose, polyethylene glycol, glycerin, polyvinyl alcohol, or oil containing drops) for rubbing into the skin.
- the formulations may have preservatives or be preservative-free (for example in a single-use container).
- Systemic formulations include those designed for administration by injection, for example, subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, oral, or pulmonary administration.
- Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles.
- the compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent or activating agents for activating the prodrug.
- the formulations for injection may be presented in unit dosage form, for example, in ampules or in multidose containers, and may contain added preservatives. They may also be provided in syringes, for example syringes with needles from injection of the drug into the skin, for example at the site of a bacterial infection (such as a S. aureus infection).
- the injectable formulation may be provided in powder form for reconstitution with a suitable vehicle, including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc., before use.
- a suitable vehicle including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc.
- the powder can include an activating agent for a prodrug, which activates the prodrug when the powder is solubilized in a vehicle.
- the active compound(s) may be dried by any art-known technique, such as lyophilization, and reconstituted prior to use.
- the topical formulation may be prepared in a variety of forms. Solids are generally firm and non-pourable and commonly are formulated as a bar or stick, or in particulate form; solids may be opaque or transparent, and optionally may contain solvents (including water and alcohol), emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and active ingredients. Creams and lotions are often similar to one another, differing mainly in their viscosity (creams are typically thicker and more viscous than lotions); both lotions and creams may be opaque, translucent or clear and often contain emulsifiers, solvents (including water and alcohol) and viscosity adjusting agents.
- Lotions and creams also may optionally contain moisturizers and emollients (especially in the case of skin care products), as well as fragrances, dyes/colorants, preservatives and active ingredients.
- Gels/serums may be prepared with a range of viscosities, from thick (high viscosity) to thin (low viscosity) and differ principally from lotions and creams in that gels/serums are usually clear rather than opaque.
- gels/serums often contain emulsifiers, solvents (including water and alcohol) and viscosity adjusters, and may also contain moisturizers and emollients, fragrances, dyes/colorants, preservatives and active ingredients.
- Aqueous liquids are thinner than creams, lotions or gels, and are generally transparent; liquids usually do not contain emulsifiers.
- Liquid topical products often contain other solvents in addition to water (including alcohol) and may also contain viscosity adjusters, moisturizers and emollients, fragrances, dyes/colorants/pigments, preservatives and active ingredients.
- Suitable emulsifiers for use in the formulations include, but are not limited to, Incroquat Behenyl TMS (behentrimonium methosulfate, cetearyl alcohol), non-ionic emulsifiers like polyoxyethylene oleyl ether, PEG-40 stearate, ceteareth-12 (e.g., Eumulgin B-1 manufactured by Henkel), ceteareth-20 (e.g., Eumulgin B-2 manufactured by Henkel), ceteareth-30, Lanette O (manufactured by Henkel; ceteareth alcohol), glyceryl stearate (e.g., Cutina GMS manufactured by Henkel), PEG-100 stearate, Arlacel 165 (glyceryl stearate and PEG-100 stearate), steareth-2 and steareth-20, or combinations/mixtures thereof, as well as cationic emulsifiers like stearamidopropyl dimethylamine
- Suitable additional and adjunct ingredients which may be included in the formulations include, but are not limited to, abrasives, absorbents, anti-caking agents, anti-foaming agents, anti-static agents, astringents (e.g., witch hazel, alcohol, and herbal extracts such as chamomile extract), binders/excipients, buffering agents, chelating agents (e.g., Versene EDTA), film forming agents, conditioning agents, opacifying agents, pH adjusters (e.g., citric acid and sodium hydroxide), and protectants.
- CTFA Cosmetic, Toiletry, and Fragrance Association
- CTFA Cosmetic Ingredient Handbook, 2nd edition, eds. John A. Wenninger and G. N. McEwen, Jr.
- kits for inhibiting bacterial growth, infection, and/or skin colonization comprising administering a disclosed antimicrobial factor(s) to a subject.
- the bacteria is a Staphylococcus species, such as S. aureus or methicillin-resistant Staphylococcus aureus (MRSA).
- composition including the antimicrobial factor can be administered to a subject in need of treatment using any suitable means known in the art.
- Methods of administration include, but are not limited to, topical, intradermal, intramuscular, intraperitoneal, parenteral, subcutaneous, rectal, intranasal, inhalation, or oral administration.
- the composition is administered topically.
- the composition is administered orally or intravenously.
- the composition is administered orally, intravenously, or topically.
- Therapeutic agents can be administered in any suitable manner, preferably with pharmaceutically acceptable carriers.
- Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present disclosure.
- the pharmaceutically acceptable carriers (vehicles) useful in this disclosure are conventional. Remington: The Science and Practice of Pharmacy , The University of the Sciences in Philadelphia, Editor, Lippincott, Williams, & Wilkins, Philadelphia, PA, 21 st Edition (2005), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic agents.
- Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
- compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.
- the disclosed topical compositions are suitable for topical application to the skin of a subject, wherein the subject is a human or non-human animal.
- the topical composition is suitable for use by an adult or child, such as a child two years of age or older.
- the topical composition may be used to treat or inhibit bacterial skin infection, such as infection with S. aureus .
- the subject may apply an amount (typically a thin layer) of the topical composition sufficient to cover a portion of or an entire affected area, wherein the affected area is an area with bacterial infection (such as an area with dermatitis, cellulitis, or an abscess).
- the infection may be intradermal or subcutaneous.
- the topical composition is rubbed or massaged into the affected skin or is applied to a wound.
- the composition is administered at least once per day, for example, 1-6 times daily (such as 1, 2, 3, 4, 5, or 6 times per day). In other embodiments, the composition is administered less frequently, such as every other day, every three days, once per week, or less. The administration may be for a sufficient period of time to treat or inhibit a bacterial infection (such as a S. aureus infection), for example for 2 or more days (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days or more). In one embodiment, the composition is provided in a sustained release format, such as an adhesive patch which is applied to the skin (such as an affected area).
- a sustained release format such as an adhesive patch which is applied to the skin (such as an affected area).
- Such adhesive patches generally have an adhesive layer, which is applied to a person's skin, a depot or reservoir for holding the active agent(s), and an exterior surface that prevents leakage of the active agent from the depot.
- the exterior surface of a patch is typically non-adhesive.
- antibiotic therapies include, but are not limited to clindamycin, erythromycin, tetracycline, minocycline, doxycycline, penicillin, ampicillin, carbenicillin, methicillin, cephalosporins, vancomycin, and bacitracin, streptomycin, gentamycin, chloramphenicol, fusidic acid, ciprofloxin and other quinolones, sulfonamides, trimethoprim, dapsone, isoniazid, teicoplanin, avoparcin, synercid, virginiamycin, cefotaxime, ceftriaxone, piperacillin, ticarcillin, cefepime, cefpirome, rifampicin, pyrazinamide, ciprofloxacin, levofloxacin, enrofloxacin
- the subject has an infection with S. aureus (such as skin infection or a systemic infection with S. aureus ).
- the subject has an infection with an antibiotic-resistant S. aureus (such as MRSA or VRSA).
- Treatment with a disclosed Malassezia antimicrobial factor can in some examples result in the antibiotic-resistant S. aureus becoming antibiotic-sensitive again, for example, sensitive to a ⁇ -lactam antibiotic, such as methicillin or vancomycin.
- the methods include treating a subject with a MRSA or VRSA infection with a disclosed composition including one or more Malassezia antimicrobial factors, followed by treatment with a ⁇ -lactam antibiotic.
- treatment with the ⁇ -lactam antibiotic is at least about 4 hours after treatment with a disclosed composition (for example, at least about 8 hours, at least about 12 hours, at least about 24 hours, at least about 2 day, at least about 4 days, or more, after treatment with a disclosed composition).
- Malassezia species were maintained on/in mDixon media (1 liter: 36 g Malt Extract, 20 g Ox-bile, 10 mL Tween 40, 6 g Peptone, 2 mL Glycerol, 2 mL Oleic Acid, and 15 g Agar) at 30° C.
- S. aureus strains were maintained on/in Tryptic Soy Broth (TSB) or Agar (TSA) at 37° C. unless otherwise stated.
- Other staphylococci were maintained in the same manner as S. aureus.
- yeast-bacteria in vitro antagonism assays For adjacent growth assays, the yeast strains were grown in 12.5 mL mDixon in shaking flasks for 96 h at 30° C., 180 rpm. Yeast were collected through centrifugation at 5,000 ⁇ g for 2 min and resuspended in fresh mDixon media to an OD600 of 1. 10 ⁇ L of yeast suspension was plated on mDixon agar for 72 h at 30° C. S. aureus 5 mL overnight cultures inoculated with a single colony were centrifuged at 5,000 ⁇ g for 1 min to collect bacterial cells and resuspend in mDixon to an OD600 of 0.1. Adjacent to the mature yeast colony, 15 of the bacterial cell suspension was plated. Spots were dried at room temperature and then incubated for 24-48-h at 30° C.
- CFS cell-free supernatant
- yeast strains were grown in 12.5 mL mDixon in shaking flasks for 96-h at 30° C., 180 rpm. Supernatant was collected through centrifugation at 5,000 ⁇ g for 2 min and yeast cells discarded. The pH of the supernatant was measured and an mDixon pH-match was generated by addition of HCl. Both the pH-matched mDixon and supernatant were filter-sterilized using a 10 mL syringe fitted to a 0.22 ⁇ m syringe driven filter. Both the CFS and pH-matched mDixon were stored at 4° C. for a maximum of 2 weeks and warmed before use at 37° C. for 15 min.
- S. aureus was grown overnight in 5 mL TSB at 37° C., 200 rpm. After ⁇ 16 hours, 1:10 dilution was from the overnight culture was made in fresh TSB and incubated for 1 h at 37° C., 200 rpm so that S. aureus was in late exponential phase (OD600 of ⁇ 1). S. aureus cells were collected through centrifugation at 5,000 ⁇ g for 1 min and resuspended in mDixon. Control conditions were prepared by mixing fresh mDixon 1:1 with pH-matched and treatment conditions were prepared by mixing fresh mDixon 1:1 with CFS. S.
- aureus was inoculated into these conditions to a final OD600 of 0.02 and incubated at 37° C. for 0-6 h at 200 rpm. After incubation, the control or treatment conditions were serially diluted in sterile water and dilutions plated on TSA and incubated overnight at 37° C. to enumerate CFUs. The assay was performed similarly with different Malassezia species and staphylococcal species.
- CFS prepared from M. sympodialis cultures as described above or pH-matched mDixon control was incubated in a dry heat block at 98° C. for 30 min.
- pH treatment the CFS and pH-matched control were adjusted to pH 6 through the addition of NaOH and then filter-sterilized with a 0.22 ⁇ m syringe-driven filter.
- resin treatment 1.25 mL of CFS or 1.25 mL pH-matched mDixon control were incubated at room temperature on a platform shaker at 80 rpm with 0.25 g of Bio-Rad Bio-Beads SM-2 Resin for 3 hours.
- the four populations were inoculated to an OD600 of 0.02 and incubated at 37° C., 200 rpm for 8 hours. After 8 h, 50 ⁇ L was taken for serial dilution and CFU enumeration on TSB. The remaining 0.45 mL was inoculated into 5 mL of TSB and incubated for 15 h at 37° C., 200 rpm. S. aureus does not grow robustly in mDixon during the 8-h exposure, so this incubation in TSB allowed for expansion of the surviving population. After 15 h, the 1:10 subculture was performed in TSB, and the second passage was set up the same as the first.
- Genome sequencing and variant calling Colonies of interest isolated from the CFS-resistant evolved populations were selected for genome sequencing. Genome DNA was extracted with the Qiagen DNeasy® Blood & Tissue Kit following the protocol for preparation from gram positive bacteria. Specifically, lysostaphin (20 mg/mL) was included in the initial lysis steps. DNA was quantified with QubitTM dsDNA BR Assay kit. Genome sequencing was performed through the Microbial Genome Sequencing Center (Pittsburgh, PA). Illumina sequencing was performed on a NextSeq 2000 platform. Variant calling was performed using breseq. S. aureus MW2 was the selected reference genome for S. aureus C199.
- S. aureus growth curves were performed on a BioTek SynergyTM H1 monochromator-based multi-mode microplate reader in non-treated flat bottom 96-well plates. S. aureus grown overnight in 5 mL of TSB was subcultured 1:10 in fresh TSB for 1 h. Cells were collected through centrifugation at 5,000 ⁇ g for 1 min and resuspended in fresh TSB. For 0 ⁇ g/mL oxacillin, 4 ⁇ g/mL oxacillin, and 16 ⁇ g/mL oxacillin TSB was utilized with a starting OD600 of 0.02.
- S. aureus colonization of NativeSkin® human skin biopsy NativeSkin® biopsies of 11 mm diameter were purchased from Genoskin Inc from three separate female donors. Each biopsy was from a healthy donor and from the abdominal region. S. aureus RN4220 expressing red fluorescent protein (RFP) from the plasmid pSRFPS1 was utilized for colonization. Media without antibiotic or antifungals was used for culturing the NativeSkin® biopsies, and media was changed every 24 h. S. aureus was inoculated in 12 ⁇ L of PBS with 10 ⁇ g/mL trimethoprim for plasmid maintenance at a cell density of ⁇ 2.5 ⁇ 10 7 cells per 12 ⁇ L. Prior to inoculated S.
- RFP red fluorescent protein
- aureus was grown in TSB and washed twice with PBS. Blank biopsies inoculated with PBS were also included. Biopsies were incubated at 37° C., 5% CO 2 for 24 h. To confirm S. aureus colonization of the biopsies, biopsies were inverted in 35 mm MatTek imaging dishes with 10 mm glass diameter and imaged with a Nikon CSU-W1 SoRA Spinning Disk microscope. Biopsies were homogenized with collagenase at 37° C. followed by mechanical disruption. Serial dilutions of the homogenate were plated on TSB.
- Malassezia sympodialis is the third most abundant species of Malassezia isolated from healthy human skin. In contrast, M. furfur and M. pachydermatis are rarely isolated from healthy skin, and the latter is often found on canine skin. When tested for activity against the human bacterial pathogen Staphylococcus aureus , only the M. sympodialis isolate appeared to inhibit S. aureus growth. To assay this antagonism, the three yeast species were grown on agar plates for 72 hours until large colonies had formed. Adjacent to the yeast colonies, S. aureus was inoculated and incubated for 24 hours. While S. aureus was capable of growth adjacent-to, and in-contact-with, the M. furfur and M.
- FIG. 1 A To confirm that an exoproduct of M. sympodialis was toxic to S. aureus , the yeast strains were grown in liquid shaking cultures. Cell-free supernatants (CFS) collected from M. sympodia lis cultures after 96 hours were toxic to S. aureus when mixed 1:1 with fresh media. Two hours of exposure to the CFS of M. sympodialis resulted in greater than 100-fold reduction in colony forming units (CFUs) per mL compared to a pH-matched media control (mDixon) ( FIG. 1 B ). Similar results were observed with M. restricta and M.
- CFUs colony forming units
- FIG. 1 C This is contrasted to M. furfur CFS which was non-toxic to S. aureus and M. pachydermatis CFS. which was only slightly toxic to S. aureus ( FIG. 1 B ).
- M. sympodialis possess antimicrobial activity against S. aureus.
- S. aureus is considered a transient colonizer of healthy human skin
- diverse coagulase-negative staphylococci are part of the normal skin flora and would likely share niches with skin resident Malassezia species like M. sympodialis .
- many skin-resident commensal staphylococci are not sensitive to treatment with CFS from M. sympodialis ( FIG. 2 A ).
- the most abundant staphylococci on healthy human skin is S. epidermidis .
- S. epidermidis sensitivity to CFS treatment from M. sympodialis was heterogenous; with some strains as sensitive as S. aureus ( S. epidermidis W23) and some completely resistant ( S. epidermidis M015) ( FIG. 2 B ).
- the CFS was subjected to various treatments in an attempt to abolish toxicity.
- the toxic effector was found to be heat stable as the CFS retained toxicity after boiling for 30 minutes ( FIG. 3 A ). This suggests that the toxic effector is non-proteinaceous.
- the toxicity of the CFS was greatly reduced when the pH of the CFS was adjusted to pH 6 from pH 5.4-pH 5.6, suggesting that the effector could be ionic and that toxicity relies on ionization/deionization of the compound ( FIG. 3 A ).
- the compound can be removed from the CFS through treatment with a non-polar resin that binds organic compounds with molecular weight ⁇ 2,000 ( FIG. 3 A ). Furthermore, the compound can be eluted from the resin beads in greater than 75% methanol (data not shown). While the size of organic compounds known to bind this resin are small, the antimicrobial component of the CFS was retained above a 30 kDa molecular weight filter, suggesting that the compound aggregates in aqueous solutions (data not shown). Based on these data, the toxic effector appears to be a small, highly non-polar, non-proteinaceous organic compound.
- aureus did not grow during the 3 hour exposure to media that was pH-matched to the CFS (mDixon), and there was some toxicity to S. aureus when exposed to the media on its own, likely due to known small amounts of antimicrobial fatty acids that make up the media. Many antimicrobials that are bactericidal to non-growing bacteria target the cell membrane. Screening selected transposon insertion mutants from the Kansas Transposon Mutant Library of S. aureus for genes involved in cell-membrane homeostasis for altered CFS sensitivity led to the observation that loss of function of the fatty acid kinase (fakA) resulted in reduced CFS sensitivity. A clean deletion of fakA in S.
- fakA fatty acid kinase
- aureus cells do not survive the co-culture, one replicate revealed surviving hyperpigmented cells similar to those identified through adaptation to the CFS (data not shown). This mixed-biofilm derived hyperpigmented isolate was also found to be resistant to treatment with M. sympodialis CFS (data not shown).
- the genomes were sequenced and variant analysis performed.
- the hyperpigmented isolates had mutations in the GTP pyrophosphokinase and master regulator of the stringent response Sa-rel ( FIG. 4 E ).
- Sa-rel orchestrates the cellular response to nutrient limitation by altering numerous aspects of S. aureus physiology, including reduction in protein synthesis and amino acid metabolism.
- the two additional CFS-passaged populations contained hyperpigmented, CFS-resistant colonies with independent mutations in Sa-rel; as well as the isolate from the mixed-biofilm experiment (IsoA) ( FIG.
- FIG. 6 A Three dimensional, living human skin biopsies provide the unique opportunity to study microbial interactions in the context of human skin ( FIG. 6 A ).
- a strain of S. aureus expressing red fluorescent protein (RFP) is capable of colonizing the epidermal surface of such biopsies after 24 hours, as verified through fluorescent microscopy ( FIG. 6 B ).
- RFP red fluorescent protein
- FIG. 6 B Treatment of S. aureus -colonized biopsies with M. sympodialis CFS mixed 1:1 with PBS (+CFS) resulted in a significant reduction in recovered S. aureus CFUs compared to those treated with media (mDixon) mixed 1:1 with PBS (+pH control) across three independent skin donors ( FIG. 6 C ). While there was inter-donor variability in the overall amount of recoverable CFUs from the ‘+pH control’ condition, within each donor the treatment with M. sympodialis CFS reduced S. aureus CFUs by approximately 100-fold.
- assessing the activity of Malassezia CFS in vivo utilizes a murine skin infection model in which the hair of mice is stripped with an adhesive (typically on the back). S. aureus from an overnight culture is then added to the skin surface. Over the course of several days an abscess is formed which can be measured to assess the severity of infection. Malassezia CFS is added directly to the skin surface both before S. aureus treatment or 1 day post infection in order to assess how the presence of Malassezia exoproducts impacts abscess growth. Control mice which are treated with S. aureus or Malassezia CFS alone are included as controls.
- a bacterial sepsis model may also be used in which mice are directly injected with live S. aureus retro-orbitally. Mice are treated with a formulation of Malassezia CFS via a tail vein injection during or after S. aureus infection. Survival of mice over the course of one week is monitored for both treatment mice and those treated with S. aureus or Malassezia CFS alone to determine protection from infection. Colony forming units of S. aureus is also measured from both whole blood and the spleen of sacrificed animals in order to measure S. aureus growth during infection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions including an antibiotic factor from Malassezia are provided. In some examples, the compositions include a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell and a pharmaceutically acceptable carrier. Methods of treating an infection in a subject, such as a Staphylococcus infection are also provided.
Description
- This application is a continuation of U.S. patent application Ser. No. 17/827,244, filed May 27, 2022, which claims the benefit of U.S. Provisional Application No. 63/194,785, filed May 28, 2021, each of which is incorporated herein by reference in its entirety.
- This disclosure relates to compositions with antibiotic activity and methods of their use, particularly for inhibiting Staphylococcus aureus.
- This invention was made with government support under Grant No. R35 GM133652 awarded by the National Institutes of Health. The government has certain rights in the invention.
- As pathogens encounter new host environments, abiotic factors such as temperature, pH, and nutrient supply influence pathogen survival and disease outcomes. Equally important are the biotic factors encountered by invading pathogens including host cellular and humoral defenses as well as host-associated microbes. As a result, these resident microbes exert strong selective pressures driving pathogen evolution. Currently, examples of these influential microbial interactions are largely limited to those between bacteria, and it remains unclear how interactions with resident fungi influence pathogen evolution and disease outcomes
- Recent studies have illustrated that fungi are able to modulate bacterial growth, virulence, and antibiotic sensitivity. The human skin is a major barrier to infection and is colonized by an estimated 106 to 109 microorganisms per cm2, of which the relative abundance of fungi is estimated to be 10 times greater in some regions than observed within the gut microbiome. The gram positive bacterial pathogen Staphylococcus aureus is a chronic asymptomatic colonizer of the nose in humans, but only transiently colonizes the skin. S. aureus skin colonization is a major risk factor for skin and soft tissue infections that amount to approximately a half of a million annual hospitalization in the United States. Additionally, S. aureus skin colonization and toxin production have been associated with multiple cancers. Thus, understanding obstacles to S. aureus skin colonization is a point of great interest in promoting human health.
- Disclosed herein are antimicrobial (e.g., antibiotic) compositions derived from the fungus Malassezia. Such compositions are useful for treating or inhibiting bacterial growth or infection, particularly growth of, or infection with Staphylococcus aureus. In embodiments, the disclosed compositions include a Malassezia exoproduct, a Malassezia cell free supernatant (CFS), or a Malassezia cell; and a pharmaceutically acceptable carrier. In particular examples, the Malassezia is Malassezia sympodialis, Malassezia restricta, or Malassezia globosa. In some examples, the Malassezia exoproduct has one or more characteristics of heat resistance, binding to non-polar molecules, and pH sensitivity (for example, antimicrobial activity at pH of about 6 or less).
- In embodiments, the composition inhibits growth and/or infection with a Staphylococcus species, for example, S. aureus, methicillin-resistant S. aureus, vancomycin-resistant S. aureus, S. caprae, S. epidermidis, S. haemolyticus, or S. warneri. In some examples, the composition inhibits growth of a Staphylococcus species by at least 10-fold compared to a control.
- In some embodiments, the composition includes about 0.01%-10% w/w, 0.01-10% v/v, or 0.01-10% w/v of the Malassezia exoproduct, cell free supernatant, or cells. In additional embodiments, the composition further includes one or more additional antibiotic compounds. In some embodiments, the composition is formulated for topical administration, such as a solution, gel, ointment, cream, or suspension. In some examples, the pharmaceutically acceptable carrier is a base including a plurality of inactive ingredients.
- Also provided herein are methods of treating or inhibiting bacterial growth, infection, and/or skin colonization in a subject. The methods include administering a disclosed composition to the subject. In some embodiments, the bacteria is a Staphylococcus species (for example, S. aureus, methicillin-resistant S. aureus, vancomycin-resistant S. aureus, S. caprae, S. epidermidis, S. haemolyticus, or S. warneri). In some examples, the subject has a bacterial skin infection, such as a skin infection with S. aureus, methicillin-resistant S. aureus, or vancomycin-resistant S. aureus.
- In some embodiments, the composition is administered orally or intravenously. In other embodiments, the composition is administered topically, for example to the skin, such as at the site of a skin infection. In some examples, the methods include administering an additional antibiotic therapy to the subject, for example, prior to, concurrently with, or following treatment with the composition.
- The foregoing and other features of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
-
FIGS. 1A-1C show that Malassezia exoproducts inhibit S. aureus.FIG. 1A is an image showing S. aureus spotted on agar plates adjacent to 72 hour Malassezia colonies and grown for 24 hours. S. aureus cannot grow up to the colony.FIG. 1B is a graph showing that S. aureus colony forming units (CFUs) per mL were not significantly reduced after 2 hour treatment with cell-free supernatant (CFS) collected from M. furfur and mixed 1:1 with fresh media (50% CFS). CFS from M. pachydermatis resulted in a small but significant reduction in S. aureus CFUs/mL and CFS from M. sympodialis resulted in a significant, large (>100-fold) reduction in S. aureus CFUs/mL.FIG. 1C is a graph showing that S. aureus colony forming units (CFUs) per mL were reduced after 2 hour treatment with cell-free supernatant (CFS) collected from M. sympodialis (Ms), M. restricta (Mr), or M. globosa (Mg). -
FIGS. 2A and 2B show antimicrobial activity of M. sympodialis targets particular staphylococci.FIG. 2A is a heat-map showing forming units enumerated to calculate the proportion of bacteria surviving the indicated CFS treatment relative to the media control. Se: S. epidermidis; Sc: S. caprae; Sho: S. hominis; Sl: S. lugdunensis; Sw: S. warneri; Sca: S. capitis; Sa: S. aureus; Sha: S haemolyticus.FIG. 2B is a graph showing CFU/ml of S. aureus (strain HFH) and six S. epidermidis strains treated with 50% CFS from M. sympodialis (strain KS269) or pH-matched media control (mDixon) for 6 hours. -
FIGS. 3A and 3B show characterization of antimicrobial activity produced by M. sympodialis.FIG. 3A is a graph showing that toxicity of CFS collected from M. sympodialis KS269 was not abolished after boiling (30 min., 98° C.). Adjustment of the CFS pH from pH 5.4-5.6 topH 6 with NaOH reduced CFS toxicity to S. aureus. The toxic effector was removed from the CFS following exposure to a non-polar resin.FIG. 3B is a graph showing treatment of S. aureus with CFS was bactericidal after 3 hours, resulting in >10,000-fold reduction in S. aureus CFUs. In contrast to wild-type (WT) S. aureus, a clean deletion mutant lacking fatty acid kinase (ΔfakA) was only slightly sensitive to treatment with M. sympodialis CFS. -
FIGS. 4A-4E show S. aureus adapts to serially exposure to CFS through mutation in the stringent response regulator Sa-Rel.FIG. 4A is a schematic diagram of protocol for experimental evolution of S. aureus exposed to 50% CFS from M. sympodialis.FIG. 4B is a graph of recovered CFUs from S. aureus strain C199 exposed to a control pH matched media condition (n=1) or 50% CFS (n=3) for 12 passages. The grey box indicates the difference between the recovered ancestor CFUs from control (top) and +50% CFS (bottom) conditions at each day.FIG. 4C is an image of Ancestral, WT-like white isolates (left) and the evolved, CFS-resistant hyperpigmented yellow isolates (right).FIG. 4D is a graph of recovered CFU/mL of pH-matched media treated (mDixon) or +50% CFS treated white and yellow colonies from EVOL-P1 replicate from passage 12.FIG. 4E is a schematic diagram of Sa-Rel protein with mutations identified in the C199 strain from the experimental evolution (EVOL-P1, -P2, P3) and the mixed-biofilm experiment (IsoA) and from the additional HFH strain used in experimental evolution (HFH EVOL-P3). HD: hydrolase domain, SYNTH: synthetase domain, TGS: ThrRS, GTPase, and SpoT domain, ACT/RRM: Aspartokinase, Chorismate mutase and TyrA/RNA Recognition Motif domain. -
FIGS. 5A-5C show S. aureus growth in the presence of the β-lactam oxacillin. Growth in TSB with 0 μg/mL oxacillin (FIG. 5A ), growth in TSB with 4 μg/mL oxacillin (FIG. 5B ), and growth in TSB with 16 μg/mL oxacillin (FIG. 5C ). -
FIGS. 6A-6C show that M. sympodialis CFS reduces S. aureus survival on human skin explants.FIG. 6A is an image of an 11 mm NativeSkin® explant biopsy.FIG. 6B shows detection of red fluorescent protein (RFP)-expressing S. aureus after 24 hours on human skin biopsy at 24 hours.FIG. 6C is a graph showing S. aureus recoverable CFU on skin explants after 24 hours of S. aureus colonization followed by treatment with pH control or CFS mixed 1:1 with PBS across three independent donors. - Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. Hence “comprising A or B” means including A, or B, or A and B. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- To facilitate review of the various embodiments, the following explanations of terms are provided:
-
- Administer: As used herein, administering a composition (e.g. an antibiotic or antimicrobial composition) to a subject means to give, apply or bring the composition into contact with the subject. Administration can be accomplished by any of a number of routes, such as, for example, topical, oral, subcutaneous, intramuscular, intraperitoneal, intravenous, intrathecal or intramuscular.
- Antibiotic: A substance often produced by or derived from certain fungi, bacteria, and other organisms, that can kill or inhibit the growth of other microorganisms. Antibiotics can also be synthetically produced.
- Base: As used herein, the term “base” refers to non-active or inactive ingredients included in a composition, such as non-active ingredients suitable for preparing a cream, ointment, or gel.
- Cell free supernatant (CFS): A liquid preparation from a cell culture (such as a culture of Malassezia cells) that is substantially free of intact cells and/or cellular debris (e.g., less than about 2% or less than about 1% of the total preparation is cells and/or debris). CFS typically is prepared by centrifuging and/or filtering a cell culture to pellet cells and cellular debris and collecting the supernatant.
- Effective amount: An amount of an agent or composition that alone, or together with a pharmaceutically acceptable carrier and/or one or more additional agents, induces the desired response. Effective amounts of an agent can be determined infection, and/or skin colonization. Effective amounts also can be determined through various in vitro, in vivo, or in situ assays, including, but not limited to those described herein.
- Exoproduct: An extracellular product produced by a cell, such as a Malassezia cell. In some examples, an exoproduct is a protein, lipid, nucleic acid, exosome, small molecule or other biological product that is secreted or released by a cell, such as a Malassezia cell.
- Inactive or non-active ingredient: As used herein, the term “inactive ingredient” or “non-active ingredient” refers to components that are not required to be disclosed by the U.S. Food and Drug Administration as being added to provide a pharmaceutical effect. Inactive or non-active ingredients are added for other purposes, such as thickening, gelling, preserving, colorizing, odorizing, deodorizing, moisture retaining, drying, solubilizing, and the like. The inactive ingredients, however, may nonetheless provide a health benefit.
- Inhibiting bacterial growth: Reducing or eliminating bacterial replication and/or spread, in vitro or in vivo. Inhibition need not be complete inhibition. In some embodiments, inhibition of bacterial growth is inhibition of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80%.
- Isolated: An “isolated” or “purified” biological component (such as a nucleic acid, peptide, protein, or other component) has been substantially separated, produced apart from, or purified away from other biological components for example, other chromosomal and extrachromosomal DNA and RNA, proteins, and/or cells. Nucleic acids, peptides and proteins that have been “isolated” or “purified” thus include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids, peptides and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acids or proteins.
- The term “isolated” or “purified” does not require absolute purity; rather, it is intended as a relative term. Thus, for example, an isolated biological component is one in which the biological component is more enriched than the biological component is in its standard environment or a production vessel. Preferably, a preparation is purified such that the biological component represents at least 50%, such as at least 70%, at least 90%, at least 95%, or greater, of the total biological component content of the preparation.
- Malassezia: A genus of fungi found on the skin of humans and other animals. It is typically commensal, but can cause opportunistic infections, such as seborrheic dermatitis or atopic dermatitis. Exemplary Malassezia species include M. dermatis, M. furfur, M. globosa, M. pachydermatis, M. restricta, and M. sympodialis. In particular examples, the Malassezia species is Malassezia sympodialis. M. sympodialis is a common commensal of normal human skin microbiota; however, it can cause skin disorders such as pityriasis versicolor, seborrheic dermatitis, and atopic dermatitis in some situations.
- Exemplary reference Malassezia genomes and strains are known and are publicly available. Exemplary strains include M. sympodialis KS269, M. sympodialis ATCC 96803, M. sympodialis ATCC 42132, M. globosa ATCC MYA-4612D-5, M. globosa ATCC MYA-4612, and M. restricta ATCC MYA-4611.
-
- Pharmaceutically acceptable carrier: In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (for example, powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate. Remington: The Science and Practice of Pharmacy, 22nd ed., London, UK: Pharmaceutical Press (2013), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compositions, such as one or more antibiotic compounds.
- Staphylococcus: A genus of gram-positive spherical bacteria that occur in microscopic clusters and produce exotoxins. In 1884, Rosenbach described two pigmented colony types of staphylococci and proposed the appropriate nomenclature: Staphylococcus aureus (yellow) and Staphylococcus albus (white). The latter species is now named Staphylococcus epidermidis. More than 20 species of Staphylococcus exist, including S. aureus, S. auricularis, S. borealis, S. capitis, S. caprae, S. epidermidis, S. hominis, S. haemolyticus, S. lugodunensis, and S. warneri.
- S. aureus forms a fairly large yellow colony on rich medium. By comparison, S. epidermidis forms a relatively small white colony. S. aureus is often hemolytic on blood agar while S. epidermidis is non-hemolytic. Staphylococci are facultative anaerobes that grow by aerobic respiration or by fermentation that yields principally lactic acid. The bacteria are catalase-positive and oxidase-negative. S. aureus can grow at a temperature range of 15° C. to 45° C. and at NaCl concentrations as high as 15 percent. Nearly all strains of S. aureus produce the enzyme coagulase. In contrast, nearly all strains of S. epidermidis lack this enzyme. Thus, strains of S. epidermidis are often referred to as coagulase-negative staphylococci.
- In some examples Staphylococcus is S. aureus, which is usually a commensal of the human microbiota, but is also an opportunistic pathogen that can cause skin infections (including abscesses), respiratory infections, meningitis, toxic shock syndrome, and sepsis. S. aureus has become resistant to many antibiotics. Thus, in some examples, S. aureus also includes antibiotic-resistant S. aureus, such as methicillin-resistant S. aureus (MRSA) and/or vancomycin-resistant S. aureus (VRSA).
-
- Subject: Living multi-cellular vertebrate organism, a category that includes vertebrates, including human and non-human mammals.
- Malassezia is the dominant fungal genus on human skin. Interactions between Malassezia and bacteria are described herein, including identification of one or more compounds secreted by Malassezia that exhibit antibiotic effects. In particular examples, the one or more compounds inhibit growth of S. aureus (including MRSA), S. caprae, S. epidermidis, S. haemolyticus, and/or S. warneri. In other examples, the one or more compounds exhibit a bactericidal activity.
- Provided herein are exoproducts produced by Malassezia species (such as M. sympodialis, M. restricta, or M. globosa) capable of inhibiting growth of Staphylococcus (including S. aureus), e.g., exhibiting antimicrobial activity. In some examples, the antimicrobial factor is a compound produced by and/or secreted by Malassezia. In some examples, the Malassezia is M. sympodialis, M. restricta, or M. globosa. In some embodiments, the antimicrobial factor exhibits one or more properties including heat resistance (for example, retention of antimicrobial 98° C. or higher), binding to non-polar molecules (such as a non-polar resin), and pH sensitivity (e.g., active only at pH of about 6 or less). In some embodiments, the antimicrobial factor has a molecular weight of about 2000 Da or less (e.g., based on binding to non-polar resin as described in Example 3). In other examples, the antimicrobial factor may form aggregates of about 30 kDa or more (e.g., as described in Example 3). In some embodiments, the antimicrobial factor (such as the Malassezia exoproduct) may be a lipid or other non-polar molecule. In other embodiments, the antimicrobial factor (such as the Malassezia exoproduct) is not a protein. In additional embodiments, a fatty acid kinase (fakA) mutant of S. aureus is resistant to the antimicrobial factor.
- In some embodiments, the antimicrobial factor inhibits growth of one or more Staphylococcus species, such as inhibits growth of one or more of S. aureus, S. caprae, S. epidermidis, S. haemolyticus, and S. warneri compared to a control. In some examples, a disclosed antimicrobial factor inhibits growth of one or more of S. aureus, S. caprae, S. epidermidis, S. haemolyticus, and S. warneri by at least about 10-fold (such as at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or more) compared to a control, such as untreated S. aureus, S. caprae, S. epidermidis, S. haemolyticus, or S. warneri. In other examples, a disclosed antimicrobial factor specifically inhibits growth of one or more of S. aureus, S. caprae, S. epidermidis, S. haemolyticus, and S. warneri, for example, inhibits growth of one or more of S. aureus, S. caprae, S. epidermidis, S. haemolyticus, and S. warneri by at least about 10-fold (such as at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or more), but inhibits growth of other Staphylococcus species by less than about 10-fold (such as less than about 5-fold, less than about 2-fold, or less than 50%) compared to a control (such as the untreated Staphylococcus species).
- In some embodiments, provided herein are compositions including a Malassezia exoproduct (such as a M. sympodialis exoproduct, a M. restricta exoproduct, or a M. globosa exoproduct) capable of inhibiting growth of Staphylococcus (for example, one or more of S. aureus, MRSA, VRSA, S. caprae, S. epidermidis, S. haemolyticus, and S. warneri) and a pharmaceutically acceptable carrier. In other embodiments, provided herein are compositions including a cell-free supernatant from a Malassezia species (such as M. sympodialis, M. restricta, or M. globosa) and a pharmaceutically acceptable carrier. In still further embodiments, provided herein a compositions including Malassezia (such as M. sympodialis) cells and a pharmaceutically acceptable carrier. In some examples, the composition includes live Malassezia cells (such as active or dormant M. sympodialis, M. restricta, or M. globosa cells).
- The pharmaceutical compositions comprising the antimicrobial (e.g., antibiotic) compounds disclosed herein may be formulated in a variety of ways depending, for example, on the mode of administration and/or on the location and type of infection to be treated. For example, such pharmaceutical compositions may be formulated as pharmaceutically acceptable salts. As another example, parenteral formulations may comprise injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like. Excipients may include, for example, nonionic solubilizers, such as cremophor, or proteins, such as human serum albumin or plasma preparations. If desired, the pharmaceutical composition to be administered may also contain non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example, sodium acetate or sorbitan monolaurate.
- Certain embodiments of the pharmaceutical compositions comprising antibiotic compounds as described herein may be formulated in unit dosage form suitable for individual administration of precise dosages. The amount and route of administration of a therapeutic compound administered will depend on the subject being treated, the type and severity of the infection, and the manner of administration, and is known to those skilled in the art. Within these bounds, the formulation to be administered will contain a quantity of the antibiotic compounds disclosed herein in an amount effective to achieve the desired effect in the subject being treated (e.g., reducing or eliminating Staphylococcus pathogens).
- In some embodiments, the composition includes about 0.01-10% (w/v or v/v) of the active composition (exoproduct, cell-free supernatant, or cells), for example, about 0.01-0.1%, about 0.05%-0.5%, about 0.25%-1%, about 0.75%-1.5%, about 1-2.5%, about 2-5%, about 3-6%, about 4-8%, about 5-7.5%, or about 6-10%. In other embodiments, the composition includes about 102-109 Malassezia cells (such as M. sympodialis, M. restricta, or M. globosa cells), for example, about 102-104 cells, about 103-105 cells, about 104-106 cells, about 105-107 cells, about 106-108 cells, or about 107-109 cells.
- In some embodiments, the composition includes one or more additional antibiotic compounds, for example, one or more of clindamycin, erythromycin, tetracycline, minocycline, doxycycline, penicillin, ampicillin, carbenicillin, methicillin, cephalosporins, vancomycin, bacitracin, streptomycin, gentamycin, chloramphenicol, fusidic acid, ciprofloxin and other quinolones, sulfonamides, trimethoprim, dapsone, isoniazid, teicoplanin, avoparcin, synercid, virginiamycin, cefotaxime, ceftriaxone, piperacillin, ticarcillin, cefepime, cefpirome, rifampicin, pyrazinamide, ciprofloxacin, levofloxacin, enrofloxacin, amikacin, netilmycin, imipenem, meropenem, and inezolid.
- For topical compositions (e.g., liquids, lotions, creams, ointments, pastes, and the like), the disclosed compositions may include carriers such as solid carriers (e.g., finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like), liquid carriers (e.g., water, dimethyl sulfoxide (DMSO), alcohols, glycols, or water-alcohol/glycol blends, optionally with the aid of non-toxic surfactants), and/or thickeners (e.g., synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses, or modified mineral materials).
- For topical administration, the disclosed compositions (e.g., Malassezia exoproduct(s), CFS, or cells) may be formulated as solutions, gels, ointments, creams, suspensions, etc. Particular embodiments of formulations for use in the methods described herein include a therapeutically effective amount of the compound, a topical base, an antioxidant, an emollient, and an emulsifier. A person of skill in the art will appreciate that a therapeutically effective amount of the compound may vary, but typically the therapeutically effective amount is from 0.01% to 10% (w/w).
- Embodiments of a topical compositions include a base including a plurality of inactive ingredients. In some embodiments, the base is a topical cream or topical gel base. The inactive ingredients may include, but are not limited to, acrylates/C10-30 alkyl acrylate crosslinked polymer (e.g., Carbopol® Ultrez 21 polymer, Lubrizol Advanced Materials, Cleveland, OH), colloidal silver (e.g., Bio-Active Silver Hydrosol™, Natural Immunogenics, Inc., Pompano Beach, FL), fulvic liquid minerals, potassium sorbate, vegetable glycerin (USP grade), citric acid, water, sodium hydroxide, crosslinked poly(acrylic acid) (e.g., Carbopol® Ultrez 30 polymer), caprylyl glycol, ethylhexylglycerin, or any combination thereof. In some embodiments, sodium hydroxide functions as an emulsifier and buffer, and may thicken a polymer gel base. Colloidal silver may be utilized as an antimicrobial agent. In some embodiments, the water is purified water or positively charged acidic water. The fulvic minerals may be any of various compositions extracted from fulvic mineral bases. The topical base may include polyethylene glycol having a selected molecular weight. Particular embodiments comprise a polyethylene glycol having a molecular weight of from 3000 to 8000 daltons as a topical base. In certain embodiments, the formulation is an ointment, and may further include a water-miscible solvent, such as a polyalkylene glycol having an average molecular weight of from 200 daltons to 600 daltons. In certain embodiments the water-miscible solvent comprises PEG-400, and even more particularly PEG-400 substantially free of impurities.
- The base may include one, all, or any of the above-listed inactive ingredients, or other inactive ingredients, in any desired ratio to produce a desired viscosity, a desired dry time on the skin, a desired scent, a desired shelf life, a desired biological activity, or any other desired characteristic of property of a topical gel or cream composition. In some embodiments, the base may further comprise 0.1-5 wt % ethanol to facilitate drying of the gel of cream on a subject's skin and/or to achieve a desired viscosity. The disclosed topical compositions may be packaged in any suitable manner. For example, the topical composition may be packaged into a pump bottle (e.g., an airless pump bottle), a squeeze bottle, a plastic tube, a metallic tube, an automatic dispensing tube, an ampoule, a jar, a tin, or any other packaging material capable of containing and, optionally, preserving potency and/or efficacy of the active agents of the topical composition.
- Topical formulations for use as described herein also can include a penetration enhancer, such as dimethyl isosorbide, propylene glycol, or combinations thereof; an emollient, such as water; a surfactant, such as sorbitan monostearate, a polyethylene glycol monostearate, D-α-
tocopheryl polyethylene glycol 1000 succinate, a composition comprising glycol stearate/PEG32 stearate/PEG6 stearate, and combinations of surfactants; an antioxidant, such as butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, a tocopherol, and combinations thereof, with particular embodiments comprising butylated hydroxytoluene as an antioxidant; and an optional colorant. - In one embodiment, the formulation is a solution. In another embodiment, the formulation is a gel. In another embodiment, the formulation is a suspension. In yet another embodiment, the formulation is a cream or ointment. One embodiment is any of the aforementioned formulations in a kit for topical or local administration. In one embodiment, the formulation is a liquid, for example a homogeneous liquid or a suspension, sold in a bottle which dispenses the formulation as drops or a liquid film (for example from an applicator tip that contacts a target area of the skin to dispense the liquid substantially only on a target area of the skin to be treated). In one embodiment, the formulation is a cream or ointment, sold in a tube which dispenses the formulation to a target area of the skin. In another embodiment, the compound is provided in a viscous liquid (such as carboxylmethylcellulose, hydroxypropylmethycellulose, polyethylene glycol, glycerin, polyvinyl alcohol, or oil containing drops) for rubbing into the skin. The formulations may have preservatives or be preservative-free (for example in a single-use container).
- Systemic formulations include those designed for administration by injection, for example, subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, oral, or pulmonary administration. Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles. The compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent or activating agents for activating the prodrug. The formulations for injection may be presented in unit dosage form, for example, in ampules or in multidose containers, and may contain added preservatives. They may also be provided in syringes, for example syringes with needles from injection of the drug into the skin, for example at the site of a bacterial infection (such as a S. aureus infection).
- Alternatively, the injectable formulation may be provided in powder form for reconstitution with a suitable vehicle, including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc., before use. The powder can include an activating agent for a prodrug, which activates the prodrug when the powder is solubilized in a vehicle. To this end, the active compound(s) may be dried by any art-known technique, such as lyophilization, and reconstituted prior to use.
- The topical formulation may be prepared in a variety of forms. Solids are generally firm and non-pourable and commonly are formulated as a bar or stick, or in particulate form; solids may be opaque or transparent, and optionally may contain solvents (including water and alcohol), emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and active ingredients. Creams and lotions are often similar to one another, differing mainly in their viscosity (creams are typically thicker and more viscous than lotions); both lotions and creams may be opaque, translucent or clear and often contain emulsifiers, solvents (including water and alcohol) and viscosity adjusting agents. Lotions and creams also may optionally contain moisturizers and emollients (especially in the case of skin care products), as well as fragrances, dyes/colorants, preservatives and active ingredients. Gels/serums may be prepared with a range of viscosities, from thick (high viscosity) to thin (low viscosity) and differ principally from lotions and creams in that gels/serums are usually clear rather than opaque. Like lotions and creams, gels/serums often contain emulsifiers, solvents (including water and alcohol) and viscosity adjusters, and may also contain moisturizers and emollients, fragrances, dyes/colorants, preservatives and active ingredients. Aqueous liquids are thinner than creams, lotions or gels, and are generally transparent; liquids usually do not contain emulsifiers. Liquid topical products often contain other solvents in addition to water (including alcohol) and may also contain viscosity adjusters, moisturizers and emollients, fragrances, dyes/colorants/pigments, preservatives and active ingredients.
- Suitable emulsifiers for use in the formulations include, but are not limited to, Incroquat Behenyl TMS (behentrimonium methosulfate, cetearyl alcohol), non-ionic emulsifiers like polyoxyethylene oleyl ether, PEG-40 stearate, ceteareth-12 (e.g., Eumulgin B-1 manufactured by Henkel), ceteareth-20 (e.g., Eumulgin B-2 manufactured by Henkel), ceteareth-30, Lanette O (manufactured by Henkel; ceteareth alcohol), glyceryl stearate (e.g., Cutina GMS manufactured by Henkel), PEG-100 stearate, Arlacel 165 (glyceryl stearate and PEG-100 stearate), steareth-2 and steareth-20, or combinations/mixtures thereof, as well as cationic emulsifiers like stearamidopropyl dimethylamine and behentrimonium methosulfate, or combinations or mixtures thereof.
- Other suitable additional and adjunct ingredients which may be included in the formulations include, but are not limited to, abrasives, absorbents, anti-caking agents, anti-foaming agents, anti-static agents, astringents (e.g., witch hazel, alcohol, and herbal extracts such as chamomile extract), binders/excipients, buffering agents, chelating agents (e.g., Versene EDTA), film forming agents, conditioning agents, opacifying agents, pH adjusters (e.g., citric acid and sodium hydroxide), and protectants. Examples of each of these ingredients, as well as examples of other suitable ingredients in topical product formulations, may be found in publications by The Cosmetic, Toiletry, and Fragrance Association (CTFA). See, e.g., CTFA Cosmetic Ingredient Handbook, 2nd edition, eds. John A. Wenninger and G. N. McEwen, Jr. (CTFA, 1992).
- Also provided are methods of inhibiting bacterial growth, infection, and/or skin colonization, comprising administering a disclosed antimicrobial factor(s) to a subject. In some examples, the bacteria is a Staphylococcus species, such as S. aureus or methicillin-resistant Staphylococcus aureus (MRSA).
- The composition including the antimicrobial factor can be administered to a subject in need of treatment using any suitable means known in the art. Methods of administration include, but are not limited to, topical, intradermal, intramuscular, intraperitoneal, parenteral, subcutaneous, rectal, intranasal, inhalation, or oral administration. In particular examples, the composition is administered topically. In other examples, the composition is administered orally or intravenously. In some embodiments, the composition is administered orally, intravenously, or topically.
- Therapeutic agents can be administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present disclosure. The pharmaceutically acceptable carriers (vehicles) useful in this disclosure are conventional. Remington: The Science and Practice of Pharmacy, The University of the Sciences in Philadelphia, Editor, Lippincott, Williams, & Wilkins, Philadelphia, PA, 21st Edition (2005), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic agents.
- Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
- Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.
- In some embodiments the disclosed topical compositions are suitable for topical application to the skin of a subject, wherein the subject is a human or non-human animal. In some embodiments, the topical composition is suitable for use by an adult or child, such as a child two years of age or older. The topical composition may be used to treat or inhibit bacterial skin infection, such as infection with S. aureus. To use, the subject may apply an amount (typically a thin layer) of the topical composition sufficient to cover a portion of or an entire affected area, wherein the affected area is an area with bacterial infection (such as an area with dermatitis, cellulitis, or an abscess). The infection may be intradermal or subcutaneous. In some embodiments, the topical composition is rubbed or massaged into the affected skin or is applied to a wound.
- In some embodiments, the composition is administered at least once per day, for example, 1-6 times daily (such as 1, 2, 3, 4, 5, or 6 times per day). In other embodiments, the composition is administered less frequently, such as every other day, every three days, once per week, or less. The administration may be for a sufficient period of time to treat or inhibit a bacterial infection (such as a S. aureus infection), for example for 2 or more days (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days or more). In one embodiment, the composition is provided in a sustained release format, such as an adhesive patch which is applied to the skin (such as an affected area). Such adhesive patches generally have an adhesive layer, which is applied to a person's skin, a depot or reservoir for holding the active agent(s), and an exterior surface that prevents leakage of the active agent from the depot. The exterior surface of a patch is typically non-adhesive.
- In particular examples, prior to, during, or following administration of a disclosed composition, the subject can receive one or more additional antibiotic therapies. Examples of such antibiotic therapies include, but are not limited to clindamycin, erythromycin, tetracycline, minocycline, doxycycline, penicillin, ampicillin, carbenicillin, methicillin, cephalosporins, vancomycin, and bacitracin, streptomycin, gentamycin, chloramphenicol, fusidic acid, ciprofloxin and other quinolones, sulfonamides, trimethoprim, dapsone, isoniazid, teicoplanin, avoparcin, synercid, virginiamycin, cefotaxime, ceftriaxone, piperacillin, ticarcillin, cefepime, cefpirome, rifampicin, pyrazinamide, ciprofloxacin, levofloxacin, enrofloxacin, amikacin, netilmycin, imipenem, meropenem, inezolid, pharmaceutically acceptable salts thereof, and prodrugs thereof. Combinations of these therapies can also be administered to a subject. Generally, the additional antibiotics of use in the methods disclosed herein are formulated for topical administration; however, other routes of administration can also be utilized.
- In some examples, the subject has an infection with S. aureus (such as skin infection or a systemic infection with S. aureus). In some examples, the subject has an infection with an antibiotic-resistant S. aureus (such as MRSA or VRSA). Treatment with a disclosed Malassezia antimicrobial factor can in some examples result in the antibiotic-resistant S. aureus becoming antibiotic-sensitive again, for example, sensitive to a β-lactam antibiotic, such as methicillin or vancomycin. Thus, in some examples, the methods include treating a subject with a MRSA or VRSA infection with a disclosed composition including one or more Malassezia antimicrobial factors, followed by treatment with a β-lactam antibiotic. In some examples, treatment with the β-lactam antibiotic is at least about 4 hours after treatment with a disclosed composition (for example, at least about 8 hours, at least about 12 hours, at least about 24 hours, at least about 2 day, at least about 4 days, or more, after treatment with a disclosed composition).
- The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.
- Strains and growth conditions: Malassezia species were maintained on/in mDixon media (1 liter: 36 g Malt Extract, 20 g Ox-bile, 10
mL Tween 40, 6 g Peptone, 2 mL Glycerol, 2 mL Oleic Acid, and 15 g Agar) at 30° C. S. aureus strains were maintained on/in Tryptic Soy Broth (TSB) or Agar (TSA) at 37° C. unless otherwise stated. Other staphylococci were maintained in the same manner as S. aureus. - Yeast-bacteria in vitro antagonism assays: For adjacent growth assays, the yeast strains were grown in 12.5 mL mDixon in shaking flasks for 96 h at 30° C., 180 rpm. Yeast were collected through centrifugation at 5,000×g for 2 min and resuspended in fresh mDixon media to an OD600 of 1. 10 μL of yeast suspension was plated on mDixon agar for 72 h at 30° C. S. aureus 5 mL overnight cultures inoculated with a single colony were centrifuged at 5,000×g for 1 min to collect bacterial cells and resuspend in mDixon to an OD600 of 0.1. Adjacent to the mature yeast colony, 15 of the bacterial cell suspension was plated. Spots were dried at room temperature and then incubated for 24-48-h at 30° C.
- To generate cell-free supernatant (CFS), yeast strains were grown in 12.5 mL mDixon in shaking flasks for 96-h at 30° C., 180 rpm. Supernatant was collected through centrifugation at 5,000×g for 2 min and yeast cells discarded. The pH of the supernatant was measured and an mDixon pH-match was generated by addition of HCl. Both the pH-matched mDixon and supernatant were filter-sterilized using a 10 mL syringe fitted to a 0.22 μm syringe driven filter. Both the CFS and pH-matched mDixon were stored at 4° C. for a maximum of 2 weeks and warmed before use at 37° C. for 15 min.
- For CFS treatment assays, S. aureus was grown overnight in 5 mL TSB at 37° C., 200 rpm. After ˜16 hours, 1:10 dilution was from the overnight culture was made in fresh TSB and incubated for 1 h at 37° C., 200 rpm so that S. aureus was in late exponential phase (OD600 of ˜1). S. aureus cells were collected through centrifugation at 5,000×g for 1 min and resuspended in mDixon. Control conditions were prepared by mixing fresh mDixon 1:1 with pH-matched and treatment conditions were prepared by mixing fresh mDixon 1:1 with CFS. S. aureus was inoculated into these conditions to a final OD600 of 0.02 and incubated at 37° C. for 0-6 h at 200 rpm. After incubation, the control or treatment conditions were serially diluted in sterile water and dilutions plated on TSA and incubated overnight at 37° C. to enumerate CFUs. The assay was performed similarly with different Malassezia species and staphylococcal species.
- Treatment of Malassezia cell-free supernatant: For boiling treatment, CFS prepared from M. sympodialis cultures as described above or pH-matched mDixon control was incubated in a dry heat block at 98° C. for 30 min. For pH treatment, the CFS and pH-matched control were adjusted to
pH 6 through the addition of NaOH and then filter-sterilized with a 0.22 μm syringe-driven filter. For resin treatment, 1.25 mL of CFS or 1.25 mL pH-matched mDixon control were incubated at room temperature on a platform shaker at 80 rpm with 0.25 g of Bio-Rad Bio-Beads SM-2 Resin for 3 hours. After 3 hours, resin was removed and the pH was adjusted back to original pH with HCl. The resin treatment increased the pH from approximately pH 5.5 to pH 5.9. Following the treatments, S. aureus was exposed to untreated CFS or pH control, or the treatment groups and CFUs were enumerated as described above. - Experimental evolution of S. aureus with CFS: The experimental evolution was performed with S. aureus strain C199 (USA400) and also with S. aureus strain HFH (USA300). Four populations were maintained throughout the serial passaging: one control population with pH-matched mDixon and three treatment populations with M. sympodialis CFS mixed 1:1 with fresh mDixon media. The initial set up for the experimental evolution was similar to all other CFS treatment assays. After a 1-h subculture in TSB, S. aureus was collected and resuspended in mDixon. The four populations, at a volume of 0.5 mL, were inoculated to an OD600 of 0.02 and incubated at 37° C., 200 rpm for 8 hours. After 8 h, 50 μL was taken for serial dilution and CFU enumeration on TSB. The remaining 0.45 mL was inoculated into 5 mL of TSB and incubated for 15 h at 37° C., 200 rpm. S. aureus does not grow robustly in mDixon during the 8-h exposure, so this incubation in TSB allowed for expansion of the surviving population. After 15 h, the 1:10 subculture was performed in TSB, and the second passage was set up the same as the first. This was carried out for 12 passages. As a control during each passage, the ancestral C199 strain was also exposed to the pH control and CFS. After the passaging, aliquots from each population were inoculated onto TSA+5% sheep's blood and TSA to assess changed in colony morphology. Phenotypically diverse colonies were selected and patched on to TSA plates and subsequently tested in isolated for sensitivity to M. sympodialis CFS as described above.
- Genome sequencing and variant calling: Colonies of interest isolated from the CFS-resistant evolved populations were selected for genome sequencing. Genome DNA was extracted with the Qiagen DNeasy® Blood & Tissue Kit following the protocol for preparation from gram positive bacteria. Specifically, lysostaphin (20 mg/mL) was included in the initial lysis steps. DNA was quantified with Qubit™ dsDNA BR Assay kit. Genome sequencing was performed through the Microbial Genome Sequencing Center (Pittsburgh, PA). Illumina sequencing was performed on a NextSeq 2000 platform. Variant calling was performed using breseq. S. aureus MW2 was the selected reference genome for S. aureus C199.
- S. aureus growth curves: S. aureus growth curves were performed on a BioTek Synergy™ H1 monochromator-based multi-mode microplate reader in non-treated flat bottom 96-well plates. S. aureus grown overnight in 5 mL of TSB was subcultured 1:10 in fresh TSB for 1 h. Cells were collected through centrifugation at 5,000×g for 1 min and resuspended in fresh TSB. For 0 μg/mL oxacillin, 4 μg/mL oxacillin, and 16 μg/mL oxacillin TSB was utilized with a starting OD600 of 0.02.
- S. aureus colonization of NativeSkin® human skin biopsy: NativeSkin® biopsies of 11 mm diameter were purchased from Genoskin Inc from three separate female donors. Each biopsy was from a healthy donor and from the abdominal region. S. aureus RN4220 expressing red fluorescent protein (RFP) from the plasmid pSRFPS1 was utilized for colonization. Media without antibiotic or antifungals was used for culturing the NativeSkin® biopsies, and media was changed every 24 h. S. aureus was inoculated in 12 μL of PBS with 10 μg/mL trimethoprim for plasmid maintenance at a cell density of ˜2.5×107 cells per 12 μL. Prior to inoculated S. aureus was grown in TSB and washed twice with PBS. Blank biopsies inoculated with PBS were also included. Biopsies were incubated at 37° C., 5% CO2 for 24 h. To confirm S. aureus colonization of the biopsies, biopsies were inverted in 35 mm MatTek imaging dishes with 10 mm glass diameter and imaged with a Nikon CSU-W1 SoRA Spinning Disk microscope. Biopsies were homogenized with collagenase at 37° C. followed by mechanical disruption. Serial dilutions of the homogenate were plated on TSB.
- Malassezia sympodialis is the third most abundant species of Malassezia isolated from healthy human skin. In contrast, M. furfur and M. pachydermatis are rarely isolated from healthy skin, and the latter is often found on canine skin. When tested for activity against the human bacterial pathogen Staphylococcus aureus, only the M. sympodialis isolate appeared to inhibit S. aureus growth. To assay this antagonism, the three yeast species were grown on agar plates for 72 hours until large colonies had formed. Adjacent to the yeast colonies, S. aureus was inoculated and incubated for 24 hours. While S. aureus was capable of growth adjacent-to, and in-contact-with, the M. furfur and M. pachydermatis colonies, it was unable to grow adjacent to M. sympodialis (
FIG. 1A ). To confirm that an exoproduct of M. sympodialis was toxic to S. aureus, the yeast strains were grown in liquid shaking cultures. Cell-free supernatants (CFS) collected from M. sympodialis cultures after 96 hours were toxic to S. aureus when mixed 1:1 with fresh media. Two hours of exposure to the CFS of M. sympodialis resulted in greater than 100-fold reduction in colony forming units (CFUs) per mL compared to a pH-matched media control (mDixon) (FIG. 1B ). Similar results were observed with M. restricta and M. globosa (FIG. 1C ). This is contrasted to M. furfur CFS which was non-toxic to S. aureus and M. pachydermatis CFS. which was only slightly toxic to S. aureus (FIG. 1B ). These in vitro data suggest that M. sympodialis possess antimicrobial activity against S. aureus. - To determine if S. aureus sensitivity to M. sympodialis exoproducts is conserved across S. aureus strains, nine clinical strain of S. aureus were treated with 50% CFS from M. furfur, M. pachydermatis, or four strains of M. sympodialis (KS014, KS013, KS269, and KS270). All four strains of M. sympodialis produced exoproducts toxic to S. aureus strains, and all of the nine S. aureus strains were sensitive to treatment with the CFS from M. sympodialis. As observed above, CFS collected from M. furfur and M. pachydermatis were non-toxic or less toxic to S. aureus compared to those from M. sympodialis (
FIG. 2A ). - While S. aureus is considered a transient colonizer of healthy human skin, diverse coagulase-negative staphylococci are part of the normal skin flora and would likely share niches with skin resident Malassezia species like M. sympodialis. In accordance with this observation, many skin-resident commensal staphylococci are not sensitive to treatment with CFS from M. sympodialis (
FIG. 2A ). The most abundant staphylococci on healthy human skin is S. epidermidis. Interestingly, S. epidermidis sensitivity to CFS treatment from M. sympodialis was heterogenous; with some strains as sensitive as S. aureus (S. epidermidis W23) and some completely resistant (S. epidermidis M015) (FIG. 2B ). - To identify the toxic effector produced by M. sympodialis, the CFS, or mDixon media, was subjected to various treatments in an attempt to abolish toxicity. The toxic effector was found to be heat stable as the CFS retained toxicity after boiling for 30 minutes (
FIG. 3A ). This suggests that the toxic effector is non-proteinaceous. Additionally, the toxicity of the CFS was greatly reduced when the pH of the CFS was adjusted topH 6 from pH 5.4-pH 5.6, suggesting that the effector could be ionic and that toxicity relies on ionization/deionization of the compound (FIG. 3A ). Lastly, the compound can be removed from the CFS through treatment with a non-polar resin that binds organic compounds with molecular weight <2,000 (FIG. 3A ). Furthermore, the compound can be eluted from the resin beads in greater than 75% methanol (data not shown). While the size of organic compounds known to bind this resin are small, the antimicrobial component of the CFS was retained above a 30 kDa molecular weight filter, suggesting that the compound aggregates in aqueous solutions (data not shown). Based on these data, the toxic effector appears to be a small, highly non-polar, non-proteinaceous organic compound. - To determine the mechanism by which CFS from M. sympodialis kills S. aureus, CFUs from S. aureus were enumerated immediately after CFS exposure (t=0) and 3 hours after exposure. While there was no difference in CFU/mL between the CFS-exposed and control groups at 0 hours, there was a <10,000-fold reduction in S. aureus CFU/mL at 3 hours after CFS exposure compared to 0 hours (
FIG. 3B ). These data indicate that the CFS was bactericidal to S. aureus, meaning the bacteria are dying rather than simply not growing. Additionally, S. aureus did not grow during the 3 hour exposure to media that was pH-matched to the CFS (mDixon), and there was some toxicity to S. aureus when exposed to the media on its own, likely due to known small amounts of antimicrobial fatty acids that make up the media. Many antimicrobials that are bactericidal to non-growing bacteria target the cell membrane. Screening selected transposon insertion mutants from the Nebraska Transposon Mutant Library of S. aureus for genes involved in cell-membrane homeostasis for altered CFS sensitivity led to the observation that loss of function of the fatty acid kinase (fakA) resulted in reduced CFS sensitivity. A clean deletion of fakA in S. aureus (ΔfakA) confirmed that loss of the fatty acid kinase reduced CFS-sensitivity of S. aureus (FIG. 3B ). Fatty acid kinase is required for incorporation of exogenous fatty acids into the cell membrane of S. aureus. This observation further supports the hypothesis that the bactericidal activity of the M. sympodialis CFS targets the cell membrane of S. aureus. - In order to determine how S. aureus may evolve resistance to the antimicrobial activity of M. sympodialis, a methicillin-resistant S. aureus strain was experimentally evolved through serially exposure to M. sympodialis CFS as depicted in
FIG. 4A . After each exposure, or passage, in CFS or pH-matched media control, the CFUs were enumerated from a total of 12 passages. While the CFUs recovered from the control, pH-matched media, condition largely were unchanged throughout the 12 passages, the CFUs recovered from the CFS-treatment populations gradually increased (FIG. 4B ). This observation suggests that resistance to M. sympodialis CFS can evolve rapidly in S. aureus. - Within the passage 12 population of the EVOL-P1 replicate where S. aureus was exposed to M. sympodialis CFS, two distinct subpopulations were apparent: white, WT-like colonies and hyperpigmented yellow colonies (
FIG. 4C ). When individual clones from each of these subpopulations were selected and treated with M. sympodialis CFS, the white colonies were sensitive to the CFS treatment similar to the WT strain, while the yellow colonies were resistant to the CFS treatment (FIG. 4D ). A similar hyperpigmented colony type was also isolated during an independent experiment where S. aureus was exposed to M. sympodialis yeast cells in a mixed biofilm. While the majority of S. aureus cells do not survive the co-culture, one replicate revealed surviving hyperpigmented cells similar to those identified through adaptation to the CFS (data not shown). This mixed-biofilm derived hyperpigmented isolate was also found to be resistant to treatment with M. sympodialis CFS (data not shown). - To determine the mutations underlying the CFS resistance of the hyperpigmented strains, both from the CFS-exposure experiment and the mixed-biofilm experiment, the genomes were sequenced and variant analysis performed. Within the EVOL-P1 replicate, the hyperpigmented isolates had mutations in the GTP pyrophosphokinase and master regulator of the stringent response Sa-rel (
FIG. 4E ). Sa-rel orchestrates the cellular response to nutrient limitation by altering numerous aspects of S. aureus physiology, including reduction in protein synthesis and amino acid metabolism. Interestingly, the two additional CFS-passaged populations contained hyperpigmented, CFS-resistant colonies with independent mutations in Sa-rel; as well as the isolate from the mixed-biofilm experiment (IsoA) (FIG. 4E ). Lastly, when the experiment was performed with an independent strains of S. aureus, hyperpigmented CFS-resistant colonies were evolved that contained a mutation in Sa-rel. Together these data indicated that resistance to M. sympodialis CFS can evolve through mutations within the stringent response regulator Sa-rel. - Low level activation of the stringent response is known to result in β-lactam homogenous resistance in strains of S. aureus that are already clinically considered to be resistant to β-lactam antibiotics. Homogenous resistance phenotypically resembles a 2-8 fold increase in minimum inhibitory concentration. To determine if the mutations in Sa-rel that confer CFS-resistance in S. aureus also confer homogenous, or hyper-resistance, to β-lactam antibiotics, the Ancestor and CFS-resistant strains were grown with super MIC concentrations of oxacillin. The oxacillin MIC for the ancestral strain was 4-8 μg/mL in rich media (tryptic soy broth, TSB). In TSB with 0 μg/ml oxacillin there was no difference in growth between the strains (
FIG. 5A ). However, at both 4 μg/mL (FIG. 5B ) and 16 μg/mL (FIG. 5C ) oxacillin, the CFS-resistant strains with Sa-rel mutations (EVOL-P1 Y1 and IsoA) were able to grow robustly while the WT, and WT-like strains (EVOL-P1 W1) were not. Interestingly, clinical isolates of S. aureus have been identified with similar Sa-rel mutations, low activation of the stringent response, and increased resistance to β-lactam antibiotics such as oxacillin. From these results, it is reasonable to hypothesize that the Sa-rel mutations that confer CFS-resistance in S. aureus also activate the stringent response and have additional consequences increased antibiotic resistance. - Three dimensional, living human skin biopsies provide the unique opportunity to study microbial interactions in the context of human skin (
FIG. 6A ). A strain of S. aureus expressing red fluorescent protein (RFP) is capable of colonizing the epidermal surface of such biopsies after 24 hours, as verified through fluorescent microscopy (FIG. 6B ). Treatment of S. aureus-colonized biopsies with M. sympodialis CFS mixed 1:1 with PBS (+CFS) resulted in a significant reduction in recovered S. aureus CFUs compared to those treated with media (mDixon) mixed 1:1 with PBS (+pH control) across three independent skin donors (FIG. 6C ). While there was inter-donor variability in the overall amount of recoverable CFUs from the ‘+pH control’ condition, within each donor the treatment with M. sympodialis CFS reduced S. aureus CFUs by approximately 100-fold. - While this example describes methods utilizing Malassezia CFS, it is understood that the methods can also utilize Malassezia exoproducts and/or Malassezia cells.
- In some examples, assessing the activity of Malassezia CFS in vivo utilizes a murine skin infection model in which the hair of mice is stripped with an adhesive (typically on the back). S. aureus from an overnight culture is then added to the skin surface. Over the course of several days an abscess is formed which can be measured to assess the severity of infection. Malassezia CFS is added directly to the skin surface both before S. aureus treatment or 1 day post infection in order to assess how the presence of Malassezia exoproducts impacts abscess growth. Control mice which are treated with S. aureus or Malassezia CFS alone are included as controls.
- In addition to a skin infection model, a bacterial sepsis model may also be used in which mice are directly injected with live S. aureus retro-orbitally. Mice are treated with a formulation of Malassezia CFS via a tail vein injection during or after S. aureus infection. Survival of mice over the course of one week is monitored for both treatment mice and those treated with S. aureus or Malassezia CFS alone to determine protection from infection. Colony forming units of S. aureus is also measured from both whole blood and the spleen of sacrificed animals in order to measure S. aureus growth during infection.
- In view of the many possible embodiments to which the principles of the disclosure may be applied, it should be recognized that the illustrated embodiments are only examples and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Claims (20)
1. A composition comprising a Malassezia exoproduct, a Malassezia cell-free supernatant, or a live Malassezia cell; and a pharmaceutically acceptable carrier.
2. The composition of claim 1 , wherein the composition comprises the Malassezia exoproduct.
3. The composition of claim 1 , wherein the composition comprises the Malassezia cell-free supernatant.
4. The composition of claim 1 , wherein the composition comprises the live Malassezia cell.
5. The composition of claim 1 , wherein the Malassezia comprises Malassezia dermatis, Malassezia furfur, Malassezia globosa, Malassezia pachydermatis, Malassezia restricta, or Malassezia sympodialis.
6. The composition of claim 5 , wherein the Malassezia comprises Malassezia sympodialis.
7. The composition of claim 1 , wherein the composition inhibits growth of a Staphylococcus species by at least 10-fold compared to a control.
8. The composition of claim 7 , wherein the Staphylococcus species is S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), S. caprae, S. epidermidis, S. haemolyticus, or S. warneri.
9. The composition of claim 1 , wherein the Malassezia exoproduct exhibits one or more of heat resistance, binding to non-polar molecules, and pH sensitivity.
10. The composition of claim 9 , wherein the pH sensitivity comprises antimicrobial activity at pH of about 6 or less.
11. The composition of claim 10 , wherein the composition has a pH of about 6 or less.
12. The composition of claim 11 , wherein the composition has a pH of about 5.4 to about 6.
13. The composition of claim 1 , wherein the composition comprises about 0.01%-10% w/w, 0.01-10% v/v, or 0.01-10% w/v of the Malassezia exoproduct, Malassezia cell free supernatant, or live Malassezia cells.
14. The composition of claim 1 , further comprising an additional antibiotic compound.
15. The composition of claim 1 , wherein the composition is formulated for topical administration.
16. The composition of claim 15 , wherein the topical formulation comprises a solution, a gel, an ointment, a cream, a lotion, a paste, or a suspension.
17. The composition of claim 15 , wherein the pharmaceutically acceptable carrier is a base comprising a plurality of inactive ingredients.
18. A composition comprising a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell; and a pharmaceutically acceptable carrier, wherein the composition is formulated for topical administration.
19. The composition of claim 18 , wherein the topical formulation comprises a gel, an ointment, a cream, a lotion, or a paste.
20. The composition of claim 18 , wherein the topical formulation comprises an alcohol or a fragrance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/381,047 US20240043479A1 (en) | 2021-05-28 | 2023-10-17 | Malassezia factor with antibiotic activity |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163194785P | 2021-05-28 | 2021-05-28 | |
US17/827,244 US11820799B2 (en) | 2021-05-28 | 2022-05-27 | Malassezia factor with antibiotic activity |
US18/381,047 US20240043479A1 (en) | 2021-05-28 | 2023-10-17 | Malassezia factor with antibiotic activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/827,244 Continuation US11820799B2 (en) | 2021-05-28 | 2022-05-27 | Malassezia factor with antibiotic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240043479A1 true US20240043479A1 (en) | 2024-02-08 |
Family
ID=84193796
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/827,244 Active US11820799B2 (en) | 2021-05-28 | 2022-05-27 | Malassezia factor with antibiotic activity |
US18/381,047 Pending US20240043479A1 (en) | 2021-05-28 | 2023-10-17 | Malassezia factor with antibiotic activity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/827,244 Active US11820799B2 (en) | 2021-05-28 | 2022-05-27 | Malassezia factor with antibiotic activity |
Country Status (1)
Country | Link |
---|---|
US (2) | US11820799B2 (en) |
-
2022
- 2022-05-27 US US17/827,244 patent/US11820799B2/en active Active
-
2023
- 2023-10-17 US US18/381,047 patent/US20240043479A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220380416A1 (en) | 2022-12-01 |
US11820799B2 (en) | 2023-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102341105B (en) | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications | |
CN101240013B (en) | High purity lipopeptides, lipopeptide micelles, processes for preparing same | |
US20210379120A1 (en) | Therapeutic treatment of skin disease with recombinant commensal skin microorganisms | |
US10077293B2 (en) | Antimicrobial peptide analogues derived from abalone (Haliotis discus) and antimicrobial pharmaceutical composition containing the same | |
KR20180002710A (en) | Antimicrobial therapy | |
WO1997018827A1 (en) | Compositions and methods for the prevention and treatment of oral mucositis | |
US6025326A (en) | Compositions and methods for the prevention and treatment of oral mucositis | |
EP3148558B1 (en) | Anti-bacterial lysate of probiotic bacteria | |
Min et al. | Antibacterial and antibiofilm activities of a novel synthetic cyclic lipopeptide against cariogenic Streptococcus mutans UA159 | |
JP2017526627A (en) | Acinetobacter lysin | |
Memariani et al. | Mechanism of action and in vitro activity of short hybrid antimicrobial peptide PV3 against Pseudomonas aeruginosa | |
US20210283215A1 (en) | Bacteriotherapy against proprionibacterium acnes for the treatment of acne | |
TWI403330B (en) | Low hemolysis antibacterial peptide pharmaceutical compositions and use thereof | |
JP6900324B2 (en) | Antimicrobial peptides | |
WO2022087065A1 (en) | Antimicrobial biosensors | |
Lan et al. | Conformation dependent architectures of assembled antimicrobial peptides with enhanced antimicrobial ability | |
US11820799B2 (en) | Malassezia factor with antibiotic activity | |
Suwandecha et al. | Novel antimicrobial peptide specifically active against Porphyromonas gingivalis | |
US20130337095A1 (en) | Antimicrobial composition and its method of use | |
Dasagrandhi et al. | Sclerotiorin: A novel azaphilone with demonstrated membrane targeting and dna binding activity against methicillin-resistant staphylococcus aureus | |
US20240041976A1 (en) | Composition and use | |
US20240058395A1 (en) | Antimicrobial therapy | |
CA2238429A1 (en) | Compositions and methods for the prevention and treatment of oral mucositis | |
JP2024508541A (en) | skin probiotics | |
US20100048476A1 (en) | Novel use of bacteriocin derived from enterococcus faecalis sl-5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF OREGON, OREGON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARBER, MATTHEW;KOWALSKI, CAITLIN;SIGNING DATES FROM 20220804 TO 20220808;REEL/FRAME:065296/0824 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |